

UC Davis

UC Davis Previously Published Works

Title

Novel Stilbene-Nitroxyl Hybrid Compounds Display Discrete Modulation of Amyloid Beta Toxicity and Structure

Permalink

<https://escholarship.org/uc/item/7c7958wr>

Authors

Hilt, Silvia

Liu, Ruiwu

Maezawa, Izumi

et al.

Publication Date

2022

DOI

10.3389/fchem.2022.896386

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



Novel Stilbene-Nitroxyl Hybrid Compounds Display Discrete Modulation of Amyloid Beta Toxicity and Structure

Silvia Hilt^{1†}, Ruiwu Liu^{1†}, Izumi Maezawa², Tatu Rojalin³, Hnin H. Aung^{4,5}, Madhu Budamagunta¹, Ryan Slez¹, Qizhi Gong⁶, Randy P. Carney³ and John C. Voss^{1,7*}

¹Department of Biochemistry and Molecular Medicine, University of California, Davis, Davis, CA, United States, ²M.I.N.D. Institute and Department of Pathology and Laboratory Medicine, University of California, Davis, Davis, CA, United States, ³Department of Biomedical Engineering, University of California, Davis, Davis, CA, United States, ⁴Division of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, University of California, Davis, Davis, CA, United States, ⁵Research Division, California Air Resource Board, Sacramento, CA, United States, ⁶Department of Cell Biology and Human Anatomy, School of Medicine, University of California, Davis, Davis, CA, United States, ⁷Paramag Biosciences Inc., Davis, CA, United States

OPEN ACCESS

Edited by:

Matthew A. Coleman,
University of California, Davis,
United States

Reviewed by:

Praveen Nekkar Rao,
University of Waterloo, Canada
Caroline Smet-Nocca,
Université de Lille, France

*Correspondence:

John C. Voss
jcvoss@ucdavis.edu

[†]These authors share first authorship

Specialty section:

This article was submitted to
Chemical Biology,
a section of the journal
Frontiers in Chemistry

Received: 15 March 2022

Accepted: 21 April 2022

Published: 26 May 2022

Citation:

Hilt S, Liu R, Maezawa I, Rojalin T, Aung HH, Budamagunta M, Slez R, Gong Q, Carney RP and Voss JC (2022) Novel Stilbene-Nitroxyl Hybrid Compounds Display Discrete Modulation of Amyloid Beta Toxicity and Structure. *Front. Chem.* 10:896386. doi: 10.3389/fchem.2022.896386

Several neurodegenerative diseases are driven by misfolded proteins that assemble into soluble aggregates. These “toxic oligomers” have been associated with a plethora of cellular dysfunction and dysregulation, however the structural features underlying their toxicity are poorly understood. A major impediment to answering this question relates to the heterogeneous nature of the oligomers, both in terms of structural disorder and oligomer size. This not only complicates elucidating the molecular etiology of these disorders, but also the druggability of these targets as well. We have synthesized a class of bifunctional stilbenes to modulate both the conformational toxicity within amyloid beta oligomers (A β O) and the oxidative stress elicited by A β O. Using a neuronal culture model, we demonstrate this bifunctional approach has the potential to counter the molecular pathogenesis of Alzheimer’s disease in a powerful, synergistic manner. Examination of A β O structure by various biophysical tools shows that each stilbene candidate uniquely alters A β O conformation and toxicity, providing insight towards the future development of structural correctors for A β O. Correlations of A β O structural modulation and bioactivity displayed by each provides insights for future testing *in vivo*. The multi-target activity of these hybrid molecules represents a highly advantageous feature for disease modification in Alzheimer’s, which displays a complex, multifactorial etiology. Importantly, these novel small molecules intervene with intraneuronal A β O, a necessary feature to counter the cycle of dysregulation, oxidative stress and inflammation triggered during the earliest stages of disease progression.

Keywords: protein misfolding, protein aggregation, oxidative stress, EPR (electron paramagnetic resonance), circular dichroism (CD), amyloid beta peptide (A β), Alzheimer’s disease

1 INTRODUCTION

The amyloid beta peptide (A β) plays central role in the etiology of Alzheimer's Disease (AD), representing the earliest and most validated marker for the disease (Selkoe and Hardy, 2016; Sperling et al., 2020). Despite decades of study, a poor understanding of the conformational/thermodynamic states of the soluble oligomeric A β peptide (A β O) continues to confound efforts to design interventions targeting this species. In recent years, clinical trials have focused on lowering extracellular A β by immunotherapy (Usman et al., 2021). The results from most studies have missed their defined endpoints, raising the question as to whether lowering extracellular A β alone is sufficient to alter disease progression. In addition, complications associated with targeting extracellular A β deposits immunotherapy are common, such as inadvertently generating A β O from deposits [e.g., "the dust raising effect" (Liu et al., 2012)].

A β O are distinguished from the A β monomers or fibrillar deposits by their neurotoxicity (Gong et al., 2003; Haass and Selkoe, 2007; Guerrero-Muñoz et al., 2014) and association to pathology in AD brains and animal models (Kayed et al., 2003; Selkoe and Hardy, 2016). For example, cell culture studies blocking A β oligomerization show protection from toxicity while compounds that promote fibril formation can be protective (Necula et al., 2007; Bieschke et al., 2011; Dutta et al., 2017). Other studies have established that A β O trigger a variety of downstream effects resulting in cognitive deficits and neuronal destruction (Shankar et al., 2008; Almeida et al., 2009; Cottart et al., 2010; Rege et al., 2014; Currais et al., 2016; Selkoe and Hardy, 2016). This includes measurements in animal and cell culture models demonstrating that A β O drives Tau phosphorylation and aggregation (Brouillette et al., 2012; Bloom, 2014; Dunning et al., 2016; Park et al., 2018).

The self-association of A β occurs through a complex interplay of different oligomeric sizes and peptide conformations, whose dynamic equilibrium is sensitive to the peptide concentration, length, modification and local environment (Cline et al., 2018). For example, smaller species have been identified as causing synaptic dysfunction, whereas larger oligomers are associated with overall neurotoxicity (Figueiredo et al., 2013). Thus, identifying a single pathogenic species *via* a defined size and conformational state common to the various intra- and extracellular milieus is unlikely. While it is not possible for synthetic A β O preps to fully recapitulate the heterogeneity and post-translational modifications of A β assemblies found *in vivo*, a multitude of studies suggest that preparations of mid-sized oligomers (>50 kDa) correlate strongest along various pathways of neurotoxicity and cellular dysregulation (Cline et al., 2018; Shea et al., 2019). These oligomers are structurally disordered, react with the conformational antibody A11, ranging in size from the dodecamer up to 150 kDa. The pathogenic conformation of the peptides within these assemblies is still unknown, although pathogenic conformations have been proposed including the β -sheet edge (Yoshiike et al., 2008), exposure of hydrophobic patches (Ladiwala et al., 2012), alpha-sheet secondary structure (Shea et al., 2019), or alternative states of the hairpin region of the peptide that

correlate to a "toxic" turn (Murakami, 2014; Silverman et al., 2018).

A β O in brain tissue are found in both extracellular and intracellular compartments (Oakley et al., 2006; Oddo et al., 2006; Pensalfini et al., 2014). While disease diagnosis relies on extracellular amyloid, the pool of intracellular A β may play a greater role in the initiation of AD (Takahashi et al., 2017). Intraneuronal A β precedes both intracellular NFT and extracellular amyloid deposits (Knobloch et al., 2007; Pensalfini et al., 2014) and has profound effects on neuronal health (Takahashi et al., 2017). There is also accumulating evidence that suggests that intraneuronal A β 42 is a major risk factor for neuronal loss and a trigger for the A β cascade of pathological events (Kienlen-Campard et al., 2002). Because intraneuronal A β precedes extracellular amyloid deposits and pTau filament formation, small molecules with access to the brain and cell interior may have a superior potential to intervene at the earliest stages of AD. Small molecules also offer flexibility in the ability to engage more than one type of misfolded protein, which may be key as increasing evidence indicates a direct influence among the various misfolded proteins (A β , Tau, α -Syn, TDP-43) associated with neurodegenerative proteinopathies (Colom-Cadena et al., 2013; Limanaqi et al., 2020).

The multifactorial nature of AD is commonly recognized, implying the involvement of several neurobiological targets in the initiation and development of this neurodegenerative disease. This challenge may in part be related to the complexity and dynamic nature of the A β O, leading to a multitude of reported mechanisms for its cytotoxicity (Kayed and Lasagna-Reeves, 2012). One important mechanism involves the elevation of reactive oxygen species (ROS), as oxidative damage can be considered the earliest known biochemical marker in the AD brain (Gong et al., 2003). A β O triggers oxidative stress in neurons, whereas oxidative stress increases A β production and/or clearance (Jo et al., 2010; Sultana and Butterfield, 2010). This process propagates a circular cascade of increased A β and ROS production (Swerdlow et al., 2014), which can also trigger microglial activation and Tau phosphorylation and misfolding (Maccioni et al., 2010; Rudenko et al., 2019).

Stilbenes such as resveratrol have shown therapeutic potential in models for AD and other neurodegenerative diseases (Rege et al., 2014; Ahmed et al., 2017; Drygalski et al., 2018). For example, resveratrol promotes A β clearance (Marambaud et al., 2005; Moussa et al., 2017), alters A β structure and aggregation properties (Ladiwala et al., 2010; Ge et al., 2012; Fu et al., 2014), and attenuates inflammation and oxidative stress in models for dementia and neurodegenerative disease (Sarubbo et al., 2017; Wang et al., 2018). Support for clinical evaluation of resveratrol in AD treatment has been shown in Alzheimer's mouse models (Karuppagounder et al., 2009; Capiralla et al., 2012; Ma et al., 2014). We have developed a new series of small molecules that alter both the conformational toxicity of A β O and provide potent, long-lived antioxidant activity. The molecules are constructed to contain a stilbene scaffold for A β O engagement and a nitroxide spin label for antioxidant activity. We have designated these bifunctional molecules as paramagnetic amyloid ligands (PALs). Here we show five chemically distinct

PAL molecules for their effect on A β O structure and assembly, as well as their ability to protect against A β O toxicity and oxidative stress.

2 MATERIALS AND METHODS

2.1 Materials

Amyloid beta (A β) peptide (1–40) was purchased from EZBiolab Inc., Carmel, IN, United States. A β ^{TOAC26} was synthesized by Prof. Lorigan and co-workers at Miami University (Petrlova et al., 2012). Hoechst Blue 3342 nuclear stain and oligomer A11 polyclonal antibody were purchased from Thermo Fisher, Waltham, MA, United States. CellROX (Deep Red; lex/lem 640/665 nm) was purchased from Life Technologies, Carlsbad, CA, United States. Opti-Minimal Essential Medium (OPTIMEM) was purchased from Invitrogen/Life Technologies, United States. PBS pH 7.4 (-Calcium Chloride, -Magnesium Chloride), Opti-MEM[®] I Reduced Serum Medium (no phenol red), DMEM (Dulbecco's modified Eagle's medium +4.5 g/L Glucose, L-Glutamine and 110 mg/L Sodium Pyruvate) and Fetal Bovine Serum (FBS) were purchased from Gibco (Carlsbad, CA, United States). 35 mm Glass Bottom Dishes (No. 1.5) purchased from MatTek. Trypan Blue Solution (0.4%) was purchased from Sigma-Aldrich. Resveratrol 3,4'-diacetate, 3-hydroxymethyl-(1-oxy-2,2,5,5-tetramethylpyrroline, 3-(2'-Iodoacetamido)-2,2,5,5-tetramethyl-1-pyrrolidinyl-1-oxyl, (1-oxyl-2,2,5,5-tetramethyl- Δ 3-pyrroline)formaldehyde, 2,2,5,5-tetramethyl-3-pyrroline-1-oxyl-3-carboxylic acid, free radical, were purchased from Toronto Research Chemicals, Toronto, Canada. Acetonitrile was purchased from Thermo Fisher Scientific (Houston, TX, United States). All other chemical reagents and solvents were purchased from Aldrich (Milwaukee, WI, United States).

2.2 Synthesis of Spin-Labeled Paramagnetic Amyloid Ligands

2.2.1 Synthesis of PMT-301

The synthetic scheme of PMT-301 is shown in **Supplementary Figure S1**. In brief, resveratrol 3,4'-diacetate (8.3 mg, 0.0266 mmol), 3-hydroxymethyl-(1-oxy-2,2,5,5-tetramethylpyrroline) (5 mg, 0.0294 mmol), triphenylphosphine (PPh₃, 8.0 mg, 0.0305 mmol), and anhydrous tetrahydrofuran (THF, 0.2 ml) were combined into a 1.5 ml microcentrifuge tube. The reaction tube was then lowered into a 42-kHz sonication bath (Cole-Parmer) and sonicated for 2 min. While sonicating, diisopropyl azodicarboxylate (DIAD, 6.6 μ l, 0.0335 mmol) was added to the reaction mixture. The reaction mixture was sonicated for 25 min. The reaction mixture was then added to a KOH solution (20 μ l, 10% aqueous solution) and stirred for 30 min at room temperature. The solution was neutralized with 0.05% trifluoroacetic acid (TFA) in acetonitrile and then submitted for purification with preparative reversed-phase high performance liquid chromatography (HPLC) using a C18 column (Vydac, 10 μ m, 2.2 cm i.d. \times 25 cm) and gradient of 25%–100% B over 34 min at a flow rate of 5 ml/min (solvent A, H₂O/0.05% TFA; B, acetonitrile/0.05% TFA). The eluant was collected and lyophilized to give powder

PMT-301. The chemical identity was confirmed with Orbitrap ESI-MS, with a calculated mass for C₂₃H₂₆NO₄ of 380.19, and observed mass of 381.20 [M+1] and 382.20 [M+2].

2.2.2 Synthesis of PMT-302

The synthetic scheme of PMT-302 is shown in **Supplementary Figure S2**. Cs₂CO₃ (20 mg, 0.0624 mmol) was added to a solution of resveratrol 3,4'-diacetate (13 mg, 0.0416 mmol) in anhydrous dimethylformamide (DMF, 1 ml) and the reaction mixture was stirred at room temperature for 45 min, 3-(2'-Iodoacetamido)-2,2,5,5-tetramethyl-1-pyrrolidinyl-1-oxyl (13.5 mg, 0.0415 mmol) was then added to the solution and the resulting mixture was stirred at room temperature overnight. The reaction mixture was added to KOH solution (20 μ l, 10% aqueous solution) and then stirred for 30 min at room temperature. The solution was neutralized with acetic acid and then purified by HPLC using the above-mentioned conditions. The eluent was lyophilized to give powder PMT-302. The chemical identity was confirmed with Orbitrap ESI-MS, with a calculated mass for C₂₄H₂₉N₂O₅ of 425.21, and observed mass of 426.22 [M+1] and 427.22 [M+2].

2.2.3 Synthesis of PMT-303

The synthetic scheme of PMT-303 is shown in **Supplementary Figure S3**. 2,2,5,5-Tetramethyl-3-pyrroline-1-oxyl-3-carboxylic acid anhydride free radical was first prepared by adding *N,N'*-dicyclohexylcarbodiimide (DCC, 56 mg, 0.271 mmol) to a solution of 2,2,5,5-tetramethyl-3-pyrroline-1-oxyl-3-carboxylic acid, free radical (100 mg, 0.542 mmol) in anhydrous dichloromethane (3 ml). The mixture was stirred at room temperature for 1 h. The precipitate was filtered out and the clear solution was concentrated and dried over vacuum to give the SL-anhydride. To a solution of resveratrol (25.3 mg, 0.11 mmol) in 1 ml anhydrous dimethyl sulfoxide (DMSO) in a round-bottomed flask, sodium hydride (11 mg, 60% dispersion in mineral oil) was added. The resulting mixture was stirred at room temperature for 20 min, followed by the addition of SL-anhydride (38.5 mg, 0.11 mmol). The reaction solution was stirred at room temperature for 2 h. The reaction was quenched with water (100 μ l), then 5 ml of cold water (with 0.1% acetic acid) was added to the solution. The solid was separated by centrifuge, redissolved in 80% acetonitrile in water (with 0.05% TFA) and purified by HPLC as described above. The chemical identity was confirmed with Orbitrap ESI-MS, with a calculated mass for C₂₃H₂₄NO₅ of 394.16, and observed mass of 395.18 [M+1] and 396.18 [M+2].

2.2.4 Synthesis of PMT-401

The synthetic scheme of PMT-401 is shown in **Supplementary Figure S4**. Stannous chloride (4.74 g, 25 mmol) was added to a solution of (*E*)-4-(4-nitrostyryl) phenol (1.2 g, 5 mmol) in ethanol (40 ml) followed by the addition of concentrated hydrochloric acid (2.0 ml). The solution was refluxed for 3 h and then cooled down to room temperature stirring overnight. Dark brown precipitate was collected by filtration and washed with small amount of ethanol to give (*E*)-4-(4-aminostyryl) phenol as HCl salt, light brown powder,

850 mg, yield 68.4%. Orbitrap ESI-MS for C₁₄H₁₃NO 211.10, Found 212.10 [M+1]. To a mixture of (*E*)-4-(4-aminostyryl)phenol HCl salt (495.4 mg, 2.0 mmol), paraformaldehyde (600 mg, 20 mmol) and sodium cyanoborohydride (378 mg, 6.0 mmol), acetic acid (20 ml) was added. The resulting mixture was heated until the solution became clear and stirred at room temperature overnight. 200 ml of water was added to the reaction solution. Sodium carbonate was added to adjust the pH to 8–9. After extraction with dichloromethane (3 ml \times 40 ml), the combined dichloromethane layer was washed with water and brine, and dried over anhydrous Na₂SO₄. The liquid was collected by filtration and concentrated *via* rotovap to give (*E*)-4-(4-(dimethylamino)styryl)phenol as a light grey solid, 144 mg, yield 30%. Orbitrap ESI-MS for C₁₆H₁₇NO 239.13, Found 240.14 [M+1]. To an 1.5 ml eppendorf tube was added (*E*)-4-(4-(dimethylamino)styryl)phenol (7.7 mg, 0.032 mmol), 3-hydroxymethyl-(1-oxy-2,2,5,5-tetramethylpyrroline) (6.0 mg, 0.0352 mmol), triphenylphosphine (PPh₃, 9.7 mg, 0.0368 mmol), and anhydrous tetrahydrofuran (THF, 0.3 ml). The reaction tube was then lowered into a 42-kHz sonication bath (Cole-Parmer) and sonicated for 2 min. While sonicating, diisopropyl azodicarboxylate (DIAD, 7.9 μ l, 0.04 mmol) was added to the reaction mixture. The reaction mixture was sonicated for 15 min, repeated three times, total 45 min. The reaction mixture was diluted with 2 ml of 50% acetonitrile/water (0.05% TFA) and then submitted for HPLC purification as described above. The eluent was collected and lyophilized to yield PMT-401 as dark brown powder. Orbitrap ESI-MS for C₂₅H₃₁N₂O₂ 391.24, found 392.25 [M+1].

2.2.5 Synthesis of PMT-402

The synthetic scheme of PMT-402 is shown in **Supplementary Figure S5**. PMT-402 was synthesized from (*E*)-4-(4-aminostyryl)phenol. Its HCl salt (200 mg) was suspended in ethanol (25 ml) and then K₂CO₃ aqueous solution was added until pH 9. Water (25 ml) was added to the suspension and mixed. After centrifuge, the solid was collected by filtration and washed with water, 70% ethanol in water and dried over vacuum to give (*E*)-4-(4-aminostyryl)phenol as brownish solid. A suspension of (*E*)-4-(4-aminostyryl)phenol (7.6 mg, 0.0357 mmol), (1-oxy-2,2,5,5-tetramethyl- Δ 3-pyrroline)formaldehyde (6 mg, 0.0357 mmol) and *p*-toluenesulfonic acid (1 mg, 0.0058 mmol) in mixture of ethanol (1.5 ml) and anhydrous THF (0.8 ml) was sonicated for 5 min until the solution became clear and stirred at room temperature for additional 15 min. After the resulting solution was cooled down with ice-water bath, NaBH₄ (27 mg, 0.714 mmol) was added. After the mixture was stirred at room temperature overnight, water (20 ml) was added, followed by addition of acetic acid to adjust the pH to 6. The precipitate was collected after centrifuge and redissolved in 80% acetonitrile in water (with 0.05% TFA) for HPLC purification as described above. The eluent was collected and lyophilized to yield PMT-402 as brownish powder. The chemical identity was confirmed with Orbitrap ESI-MS. Calcd. for C₂₃H₂₇N₂O₂: 363.21, found: 364.22 [M+1], 365.22 [M+2].

For experimental use, PALs were used from stock solutions (1 mM or 4 mM) of the agent in DMSO.

2.3 Preparation of Aqueous Amyloid Beta

Aqueous A β for A11-positive oligomer generation was prepared using modifications to the protocol reported by Chunhui et al. (2018). A β powder was dissolved to a concentration of 2.5 mg/ml in hexa-fluoro-isopropanol (HFIP), rotated overnight and stored in 0.4 ml aliquots at -80°C . An aqueous solution was then made by combining the HFIP stock to a 2 ml microfuge tube and then, while stirring, adding 1 ml of 0.1 M NaHCO₃, pH 9.6. HFIP was then removed by with nitrogen gas flow over the stirred solution until the volume reaches \sim 0.9 ml. The sample volume was QS to 1.0 ml with 0.1 M NaHCO₃, pH 9.6. The sample was then centrifuged at 15,000 rpm in a microfuge for 10 min to remove large amorphous aggregates as described previously (Altman et al., 2015). The supernatant was collected and the removal of large aggregates verified by circular dichroism as the broadening of the negative 200 nm band (Fezoui and Teplow, 2002; Hopping et al., 2014). The final concentration of A β after removal of large amorphous aggregates was \sim 0.9 mg/ml (estimated from absorbance at 280 nm).

For EPR measurements, A β _(1–40) containing the TOAC spin label at position 26 (A β ^{26TOAC}) was dissolved in HFIP at 2.5 mg/ml and combined with the native peptide (2.5 mg/ml in HFIP) at a 4:1 ratio (native:TOAC-labeled). An aqueous solution of the mixture was then obtained as described above.

Samples of oligomeric A β (A β O) were then made by combining the 0.9 mg/ml sample of A β (in 0.1 M NaHCO₃) at a 1:1 ratio with 100 mM Tris Borate (pH 7.4). After 60 min of incubation, samples were diluted to their experimental concentration with 50 mM Tris-Borate (pH 7.4) and used within 3 hours.

A β protofibrils were made by combining the 0.9 mg/ml sample of A β (in 0.1 M NaHCO₃) at a 1:1 ratio with 100 mM Tris Borate (pH 7.0), 300 mM NaF and stirring the sample for 24-h with a 4 mm magnetic stir bar. Samples were then diluted to their experimental concentration with 50 mM Tris Borate (pH 7.0), 150 mM NaF. Beta-sheet content of protofibrils was verified by circular dichroism.

2.4 Cell Culture Model Over-Expressing Intracellular Amyloid Beta

MC65 cells are a neuronal cell line showing intracellular accumulation of A β (Jin et al., 2004; Maezawa et al., 2006; Hong et al., 2007; Maezawa et al., 2008). The MC65 cells are derived from a human neuroblastoma line with conditional expression of the carboxyl-terminal 99 residues of the amyloid- β precursor protein (APP-C99) under the negative regulation of the suppressor tetracycline (TC) in the culture medium. Expression of APPC99 is induced by removing TC from cell culture medium. Proteolysis of APP-C99 by the cellular γ and β secretases generates A β . Intracellular A β is known to start to accumulate as early as 4 h after TC removal with maximal

levels at 24 h. Cell death in 3 days after removal of TC was shown to be due to the intracellular accumulation of A β O rather than to the small amounts of secreted A β (Maezawa et al., 2006).

The cytotoxicity was determined using MTT assay in the presence of TC, the results of which were comparable with data obtained using counts of viable cells based on trypan blue exclusion and the live/dead assay. Cells were treated with either DMSO or the indicated concentration of PAL at the same time as TC removal, with a uniform level of DMSO (0.05%) in all assay cultures. Data are expressed as mean percentage viability of 3×10^4 cells/well counted from $n = 3$ cultures, with parallel +TC cultures of equal numbers of cells set at 100% viability.

2.5 Detection of Intracellular Oxidative Stress Signal by Confocal Microscopy

Treated and control MC65 cell cultures were gently washed with untreated culture medium and incubated for 30 min with the ROS detection reagent CellROX, a fluorogenic probe that when oxidized develops a red fluorescent signal seen around the nuclei of cells experiencing oxidative stress. At 20 min, the cells were treated for the remaining 10 min with Hoechst Blue 3342 nuclear stain, gently washed for 15 min $\times 3$ with untreated culture medium and imaged immediately. The images of CellROX staining were collected on an Olympus Fluoview 3000 confocal laser scanning microscope. Each individual field was imaged using an 40 \times objective. Single plane confocal scans of the cultured neuronal cell areas were taken *via* sequential scanning mode using diode excitation lasers of 653 nm for CellROX Deep Red ($\lambda_{ex}/\lambda_{em} = 640/665$ nm).

Intensity comparison of CellROX emission was calculated by transforming images to 8-bit gray scale and fluorescence intensity was analyzed with Image J, FIJI for MAC OS X, using the particle analysis function (Schneider et al., 2012). Triplicate measurements of the mean fluorescence intensity were done in three randomly selected areas of each of the cell culture fields, with background correction. Statistical significance between groups was determined by ordinary one-way ANOVA test using GraphPad Prism version 7.0c for MAC OS X (GraphPad Software, La Jolla California United States), where the p value from the ANOVA is reported as a result of the Brown-Forsythe test and considered significant if $p < 0.05$ for each treatment group. All data was expressed as the mean \pm SEM.

2.6 A11 ELISA Assay

For ELISA measurements, peptide was passively bound to a 96-well Greiner FLUOTRACTM 600 high binding microplate by adding 60 μ l of 0.2 mg/ml aqueous A β solution per plate well, followed by 200 μ l of freshly made 0.1 M NaHCO₃, pH 9.6. Each assay was performed using quadruplicate wells for each sample treatment. The plates were then incubated overnight at 4 $^{\circ}$ C. Wells were then treated with 300 μ l blocking solution [50 mM Tris buffer (pH 7.4) containing 100 g/L dried milk] for 1-h, then washed twice with the same solution. Each well was then incubated with 300 μ l of 40 μ M PAL (or vehicle control) in wash buffer [50 mM Tris buffer (pH 7.4) containing 50 g/L dried milk] for 1-h, and then washed 3X with wash buffer.

Wells were then treated with 300 μ l of primary antibody in the presence of the PAL or vehicle control (A11 antibody diluted 1:1,200 in wash buffer containing 40 μ M PAL) and incubated for 2-h. Wells were then washed 3 \times with wash buffer and incubated with HRP-conjugated secondary antibody (GAR antibody diluted 1:1,200 in wash buffer). Wells were then washed $\times 3$ with wash buffer and the HRP activity quantified by luminescence by adding 150 μ l of each SuperSignal (Thermo) chemiluminescent HRP substrate reagent to each well.

2.7 Electron Paramagnetic Resonance Spectroscopy

EPR measurements were carried out in a JEOL TE-100 X-band spectrometer fitted with a loop-gap resonator as described previously (Shea et al., 2019) (JEOL United States, Peabody, MA). PALs (or vehicle control) were added to the spin-labeled A β O (80 μ M) at a final concentration of 40 μ M 30 min prior to EPR measurements, carried out on ~ 5 μ l of sample loaded into a sealed quartz capillary tube. The spectra were obtained by averaging two 2-min scans with a sweep width of 100 G at a microwave power of 4 mW and modulation amplitude optimized to the natural line width of the attached spin probe. All the spectra were recorded at room temperature.

2.8 Circular Dichroism Measurements

For Circular dichroism spectroscopy (CD) measurements, aqueous A β O was diluted with 50 mM Tris-Borate, pH 7.4 to a concentration of ~ 0.15 mg/ml with measurements made within 2-h. A β protofibrils was diluted with 50 mM Tris-Borate, 150 mM NaF, pH 7.0 to a concentration of ~ 0.15 mg/ml. PALs were added from a 4 mM stock in acetonitrile to a final concentration of 40 μ M. CD measurements were performed on a Jasco J-715 spectropolarimeter equipped with a Peltier temperature control (Quantum Northwest) set to 25 $^{\circ}$ C. For spectral acquisition, samples were placed in a 1 mm quartz cuvette and CD spectra were collected by signal averaging three scans in the region 190–260 nm using a scan speed of 20 nm/min, bandwidth of 1 nm and response time of 4 s. Prior to analysis, all spectra were baseline-subtracted from the appropriate background buffer containing either the PAL alone or the solvent vehicle (the background signals were generally indistinguishable). The percent of secondary structure was estimated by deconvolution using the BeStSel CD analysis program (Micsonai et al., 2015), which can be accessed online at <http://bestsel.elte.hu>.

2.9 Nanoparticle Tracking Analysis

For Nanoparticle Tracking Analysis (NTA) measurements, aqueous A β was diluted 1:1 with 100 mM Tris-Borate, pH 7.4 to a concentration of ~ 0.1 mg/ML with measurements made within 2-h. NTA was performed using a NanoSight model LM10 (Malvern Panalytical Ltd., United Kingdom), equipped with a violet (405 nm) laser and sCMOS camera. A daily calibration and data consistency confirmation was carried out using analytical standard quality polystyrene beads (Thermo

Fisher Scientific, MA, United States) of sizes 70, 100, and 200 nm, and silica beads (nanoComposix, CA, United States) of sizes 80, 200, and 400 nm before the actual analyte measurements. Consequently, the samples of interest were measured by optimizing the concentration on the typical NanoSight LM10 range ($\sim 10^8$ – 10^9 particles per milliliter). Thus, typically dilutions between 1–15 k fold were applied. Filtered ultrapure Milli-Q water (resistivity = 18.2 MW cm^{-1}) was used between each sample to thoroughly flush the NTA lines to confirm that the background was completely free of remnant particles before running a new sample. A 1 ml of sample was loaded into a syringe and fit into an automated syringe pump (Harvard Bioscience, MA, United States) for injection. In order to achieve rigorous and representative sampling, at minimum nine consecutive 30 s videos of each sample in flow conditions with at least 200 particle tracks present per video were recorded at camera level 12. The data was analyzed using NanoSight NTA 3.1 software with the detection threshold set to 5 and screen gain 10 to track the statistically relevant number of particles, simultaneously minimizing the distorting background artifacts.

2.10 Thioflavin T Assay

Three microliters of aqueous A β ($\sim 0.9 \text{ mg/ml}$ in NaHCO_3) were added to the wells of a black, Nunc MicroWell, 384-well nonbinding optical bottom microplate (cat # P9241-30EA) containing 50 μl of PBS. Samples were treated with PALs (18 μM) or vehicle control. Prior to each assay, a fresh 1 mM ThT (Sigma Aldrich, product # T3516) was prepared in cold DI water and filtered through a 0.22 μm syringe filter. Assays were initiated with 1 μl of ThT. ThT fluorescence was measured at room temperature, using a TECAN Infinite 200Pro plate reader, through the bottom of the plate, with of 440 nm and emission of 486 nm. The fluorescence intensity of a free ThT solution (20 μM) in PBS was used for background subtraction of the control sample and the background of ThT + PAL was subtracted from samples containing A β .

2.11 Nile Red Assay

Three microliters of aqueous A β ($\sim 0.9 \text{ mg/ml}$ in NaHCO_3) were added to the wells of a black, Nunc MicroWell, 384-well nonbinding optical bottom microplate (cat # P9241-30EA) containing 50 μl of PBS. Samples were treated with PALs (18 μM) or vehicle control. Prior to each assay, a fresh solution 1 mM Nile Red (Sigma Aldrich, product # 19123) was prepared in DMSO and centrifuged at 10,000 RPM to remove any aggregates. Assays were initiated with 1 μl of Nile Red. Nile Red fluorescence at $t = 5 \text{ h}$ was measured at room temperature, using a TECAN Infinite 200Pro plate reader, through the bottom of the plate, with of 558 nm and emission of 635 nm. The fluorescence intensity of a free Nile Red solution (20 μM) in PBS was used for background subtraction of the control sample and the background of Nile Red + PAL was subtracted from samples containing A β .

2.12 Cytokine Measurements

2.12.1 Human TGRL Isolation

The protocol for obtaining human TGRL (Protocol No. 447043) was approved by the Human Subjects Review Committee/IRB at

the University of California Davis and informed consents were obtained from all study subjects. Healthy adult human volunteers consumed a moderately high-fat meal containing at least 40% fat, and postprandial (3.5 h) blood was collected by standard venipuncture (Vacutainer K2EDTA tubes; BD, Franklin Lakes, NJ). We recruited five to six human donors/week, pooled the plasma, and isolated TGRLs. The average pooled TGRL concentration was ~ 700 – 800 mg/dl . We used 150 mg/dl concentration to treat endothelial cells in our study. For experiments, we pooled TGRL isolated from donors. Through extensive experience, we have found the data were very consistent using this method of collection and pooling of TGRLs (Aung et al., 2013; Aung et al., 2014; Aung et al., 2016). Whole blood samples were then centrifuged at 3,000 rpm for 15 min at 4°C, and the plasma fraction was collected. Sodium azide was added to the plasma as a preservative. TGRL were isolated from human plasma at a density of less than 1.0063 g/ml following an 18 h centrifugation at 40,000 rpm in a SW41 Ti swinging bucket rotor (Beckman Coulter, Sunnyvale, CA, United States) held at 14°C within a Beckman L8-70M (Beckman) ultracentrifuge. The top fraction TGRL was collected and dialyzed in Spectrapor membrane tubing (MWCO 3,500; Spectrum Medical Industries, Los Angeles, CA, United States) at 4°C overnight against a saline solution containing 0.01% EDTA. Total triglyceride content of samples was determined using the serum triglyceride determination kit (Sigma Aldrich cat # TR0100). The kit converts triglycerides to free fatty acids and glycerol. Glycerol is assayed enzymatically.

2.12.2 Cell Culture and Lipid Treatments

Human brain microvascular endothelial cells (HBMECs) were obtained from Angio-Proteome (Boston, MA, United States) and cultured in EGMTM-2MV BulletKitTM containing 5% serum (CC-3202, Lonza, Walkersville MD) in a 37°C incubator with a humidified 5% CO₂ and 95% air environment. Medium was changed every other day until 90% confluency and cells were used at passage 6. One hour prior to experiments, cell culture medium was changed to fresh medium. Cells were exposed for 3 h to the following conditions: control of media containing DMSO at a final concentration of 0.01% (control) and TGRL hydrolyzed with lipoprotein lipase (L2254, Sigma, St. Louis, MO, United States) [referred to as TGRL lipolysis product, TGRL (150 mg/dl = 1.5 mg/ml) + lipoprotein lipase (LpL; 2 U/mL)]. The final concentration of TGRL lipolysis products were diluted in media and pre-incubated for 30 min at 37°C prior to application. After the incubation with media or TGRL lipolysis products, cells were washed with cold PBS and harvested by scraping them in ice cold PBS.

To test the suppression of compounds on TGRL lipolysis products-induced gene expression, cells were pre-incubated with each individual compound of interest indicated for 30 min and followed by co-incubated with TGRL lipolysis for 3 h. These compounds are Tempo, Mito-Tempo, PMT-301, PMT-302, PMT-303, PMT-401, and PMT-402. The final concentration of each compound is 1 μM . After the incubation, the cells were washed with cold PBS and mRNA expression of ATF3, E-selectin, IL-8, IL-6, and COX-2 were analyzed.

2.12.3 mRNA Expression by Quantitative RT-PCR

Total RNA was extracted from cells in each of treatment group [control or TGRL lipolysis products (TL) or TL + individual compound of PAL] in 6-well plate (3 well per sample, $n = 3$ /group) using RNeasy Mini Kit (Qiagen, Valencia, CA, United States) including the DNA digestion step as described by the manufacturer. Sample quality was assessed using Nanodrop ND-1000 Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, United States). An aliquot equivalent to 5 μ g of total RNA extracted from each sample was reverse-transcribed to obtain cDNA in a final volume of 21 μ l consisting of buffer, random hexamers, DTT, dNTPs, and SuperScript[®] III First-Strand Synthesis System (Invitrogen). qRT-PCR with SYBR as fluorescent reporter was used to quantify the gene expression. Specific human primers were designed with Primer Express 1.0 software (Applied Biosystems) using the gene sequences (Supplementary Table S1) obtained from previously published Affymetrix Probeset IDs (Aung et al., 2014). Reactions were carried out in 384-well optical plates containing 25 ng RNA in each well. The quantity of applied RNA was normalized by simultaneously amplifying cDNA samples with glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific primers. The transcript levels were measured by real-time RT-PCR using the ABI ViiA[™]7 Real-Time PCR system (PE Applied Biosystems, Foster City, CA, United States). The PCR amplification parameters were: initial denaturation step at 95°C for 10 min followed by 40 cycles, each at 95°C for 15 s (melting) and 60°C for 1 min (annealing and extension). A comparative threshold cycle (Ct) method was used to calculate relative changes in gene transcription determined from real-time quantitative PCR experiments [Applied Biosystems user bulletin no. 2 (P/N4303859)] (Livak and Schmittgen, 2001). The threshold cycle, Ct, which correlates inversely with the target mRNA levels, was measured as the cycle number at which the SYBR Green emission increases above a preset threshold level. The specific mRNA transcripts were expressed as fold difference in the transcription of the specific mRNAs in RNA samples from the TL or TL + individual compound of PAL (Tempo or Mito-Tempo or PMT-401 or PMT-402 or PMT-101 or PMT-301 or PMT-302 or PMT-303)-treated cells compared with those from the control-treated cells.

3.12.4 Statistical Analysis

Data for changes in gene expression obtained by qRT-PCR were analyzed by GraphPad PRISM software (San Diego, CA). An unpaired student's t test was used for comparisons between treatments. Differences with $p \leq 0.05$ were considered significant. Results are expressed as MEAN \pm SEM.

3 RESULTS

3.1 Differential Potency of Stilbene Paramagnetic Amyloid Ligands

The structures of the stilbene-based PALs are shown in Figure 1. Importantly, these results demonstrate the utility of the MC65 model in measuring intracellular AD pathology such as oxidative stress (Hilt et al., 2018), Ca²⁺-dysregulation (Copenhaver et al.,

2011), activation of inflammatory pathways (Currais et al., 2016) as well as autophagy and pTau formation (Mputhia et al., 2019). In the MC65 model, expression of the progenitor of the A β peptide (C99) is repressed in the presence of tetracycline (+TC). Upon removal of tetracycline (–TC), induction of C99/A β O decreases the cell viability by ~90%. The ability of the stilbene PALs to protect against A β -induced cytotoxicity was assessed using the MC65 neuronal culture model, where the inducible expression of the C99 fragment of APP results in cell death within 72 h (Petrlova et al., 2012; Currais et al., 2016). Each of the stilbene PALs provides protection against cell death in the MC65 assay (Figure 2). However, the potency of the PAL candidates varies, with PMT-402 more than 50-times more potent than PMT-302. PMT-401 was the only PAL that could not restore viability to 100%. The poor performance of PMT-401 at higher concentrations is likely related to its poor solubility.


3.2 Stilbene Paramagnetic Amyloid Ligands Reduce Binding of the Conformation-Specific Antibody A11

The identification by Glabe and co-workers (Kayed et al., 2003) of an antibody that recognizes the pathogenic state of disparate proteins involved in neurodegeneration provides a tool for probing modulation of the A β O away from its “toxic” conformation (Necula et al., 2007). To evaluate the effect of the stilbene PAL agents on A11 recognition, we measured A11 binding to immobilized A β O with and without PAL treatment. As shown in Figure 3, treating immobilized A β O with a stoichiometric amount of the PAL agent reduces the average A11 capture by ~50%. PMT-402 appears most effective in reducing the amount of A11 recognition in this assay.

3.3 Paramagnetic Amyloid Ligands Combat A β -dependent Oxidative Stress

We have previously demonstrated the highly potent antioxidant capacity of the nitroxyl-based PALs (Hilt et al., 2018). To confirm this property in the stilbene PALs, the CellROX dye in MC65 cells was imaged for levels of reactive oxygen (ROS) species. Figure 4 illustrates the antioxidant activity of the PMT-301 PAL. Shown are confocal microscopy images of the ROS-sensitive CellROX dye (red) in live MC65 neurons. Oxidative stress is absent when expression of the progenitor of the A β peptide (C99) is repressed (+TC, top row). Induction of C99/A β production (–TC) generates high ROS levels (middle row). In contrast, as shown in the bottom row, ROS levels in –TC cells are highly (~60%) attenuated by PMT-301 treatment (see Supplementary Figure S6).

Oxidative-stress and inflammation are closely connected in neurodegenerative disorders (Bonda et al., 2010; Liu et al., 2017), so the PAL antioxidant activity is expected to also attenuate markers of inflammation. In order to access whether the PALs elicit anti-inflammatory activity independent of the A β O-driven oxidative stress, we also looked at whether any of the stilbene PALs carry anti-inflammatory activity in the human brain endothelial cell (HBMEC) model (Aung et al., 2014). In this model, TGRL



lipolysis products (TL) are used to upregulate stress-responsive transcription factor ATF3, COX-2, and proinflammatory genes (IL-6, IL-8 and E-selectin) using microarray data analysis (Aung et al., 2014) and RNA Seq analysis (Nyunt et al., 2019). TL substantially increases stress-responsive transcription factor ATF3, COX-2, and proinflammatory genes (IL-6, IL-8 and E-selectin). We previously showed that TL causes lipotoxic injury to HBMECs and this lipotoxicity occurs through stimulation of mitochondrial metabolism resulting in overproduction of superoxide radical ($O_2^{\bullet-}$) (Aung et al., 2016). Moreover, TL increased mitochondrial $O_2^{\bullet-}$ generation, ATF3-mediated inflammatory, and apoptotic responses in *in vitro* HBMECs culture (Nyunt et al., 2019). Here we analyzed the biological activity of the stilbene PALs plus two common nitroxide agents (Tempo and Mito-Tempo) on TL-induced gene expression. As a group, only PMT-401 provides broad anti-inflammatory activity as measured by gene expression. As shown in **Supplementary Figure S7**, PMT-401 significantly suppressed TL-induced ATF3, E-selectin, IL-6, IL8, and COX-2 gene expression. Additionally, COX-2 expression was suppressed by PMT-302 and PMT-303 ($p = 0.07$). Because PMT-401 is distinguished in part by its greater hydrophobicity (CLogP of 4.5, vs. CLogP values of 2.9–4.0 for the other PAL compounds), the effectiveness of nitroxide antioxidants to attenuate inflammation in the TL-activated HMEC model may rely on the compound's ability to partition into a lipophilic environment. Consistent with this notion is the lack of anti-inflammatory activity found with Tempo and Mito-Tempo treatment, and in fact increased TL-induced ATF3, E-selectin, IL-6, IL8 and COX-2 gene expression. Thus, the simple addition of a hydrophilic nitroxide is insufficient to attenuate inflammation in this model.

3.4 Target Engagement and Conformational Adaptation

In order to investigate how the stilbene PALs affect A β O conformation, CD spectroscopy was carried out to probe for secondary structure changes in the PAL-treated peptide. The

untreated early A β O generates a low amplitude CD spectrum indicative of its unstructured state (Shea et al., 2019; Clements et al., 1996) (**Figure 5**, black trace). After 24 h, the A β O sample undergoes a substantial increase in the pleated beta-sheet content as it converts into soluble protofibrils (Walsh et al., 1999; Kaye et al., 2009) (**Figure 5**, inset). While each of the stilbene PALs induce significant changes to the CD spectrum of A β O, the stilbene PALs do not order the early A β O into an α -helical or β -strand state. This finding is consistent with previous CD measurements of stilbene effects on A β O (Ladiwala et al., 2010; Feng et al., 2009). Nevertheless, each of the five PALs drive a significant change in the A β O CD spectrum, with PMT-301, PMT-302, PMT-303 and PMT-402 generating strong negative bands at 198 nm, characteristic of PP-II structure (Adzhubei et al., 2013). This response is similar to a fluorene-based PAL (Altman et al., 2015). In contrast, PMT-401 does not induce the PPII-like spectral change. Results from the fitting of the CD spectra by the BeStSel algorithm (Micsonai et al., 2015) to estimate fractions of secondary structure are given in **Table 1**. In each of the early A β O samples, the low structure folds (random coil/loop, 3_{10} - and π -helices, PP-II helix) constitute the major population before and after PAL treatment. Of the compounds that produce a PPII-like spectrum, only a marginal increase in α -helical structure is seen, accompanied by a slight decrease in the β -strand population. The effect of PMT-401 on A β O is distinguished by helical content and decreased beta content compared to the other PALs. Interestingly, PMT-401 (which displays the lowest potency in cell protection) generates a very unique CD spectrum for A β O in an aqueous solution, although a similar 204 nm minima has been reported following treatment of A β O with 10% trifluoroethanol or 50% acetonitrile (Fezoui and Teplow, 2002; Bartolini et al., 2007).

Finally, we also looked to see the effect of PAL addition to protofibrillar oligomers formed after 24-h incubation (**Figure 5**, inset). These species have much lower toxicity and lack recognition by the conformational antibody A11 (Kayed et al., 2009; Bieschke et al., 2011). Consistent with





FIGURE 2 | Neuronal protection activity of the stilbene PAL agents in the MC65 model. Removal or tetracycline from the MC65 culture media results in C99 expression and amyloid beta cytotoxicity (A). (B) shows rescue of cytotoxicity with PAL titration. Error bars are the SEM from the assay of three separate cultures.

previous findings (Walsh et al., 1999; Bartolini et al., 2007; Corsale et al., 2012; Roychaudhuri et al., 2014), the CD spectrum of the protofibril A β sample displays a high percentage of β -strand. In this more ordered species, the CD spectra of each PAL-treated preparation is similar to the untreated control, although each of the PALs enhance the conversion of the disordered components into β -strand by 7%–10% (Table 1).

3.5 Alteration of Amyloid Beta Oligomers Dye Binding

We also measured the effect of the stilbene PALs on modulating the interaction of dyes with A β O over time, whose fluorescence is influenced by its association with proteins and their aggregates.

The fluorescence of the Nile Red (NR) dye is indicative for its degree of solvation, where its quantum yield increases within more hydrophobic environments (Singh et al., 2013). The NR fluorescence intensity in the presence of A β O with and without PAL treatment is shown in Figure 6A. Each of the stilbene PALs, except for PMT-302, increases the solvent exposure of NR. We also looked at the fluorescence intensity of Thioflavin T (ThT), which is greatly amplified upon its intercalation within β -sheet structure. ThT fluorescence therefore provides a fundamental marker for A β assembly along the amyloidogenic pathway (Hellstrand et al., 2010). To evaluate the ability of the stilbene PALs to inhibit A β O conversion into a protofibril species, ThT fluorescence in the presence of A β O was measured with and without PAL treatment. Figure 6B shows the ThT signal following 24-h of incubation. These results, in combination



with the NR findings, suggest PMT-303 is highly efficient in both A β O conformational adaption and inhibition of β -sheet formation.

3.6 Effect of Paramagnetic Amyloid Ligands on Amyloid Beta Oligomers Structure


Although the CD results do not indicate conversion into a well-defined state of secondary structure, electron paramagnetic resonance (EPR) spectroscopy of A β O's reveals, that with the exception of PMT-401, the stilbene PALs trigger a major reorganization of the peptide's central region. In these experiments, Ser26 of A β was substituted with TOAC, an amino acid spin label. The TOAC nitroxide provides a sensitive indicator of both the local within the peptide and its proximity to other spin labels within the assembly (Petrlova et al., 2012; Altman et al., 2015). Thus, although CD spectroscopy reveals a lack of secondary structural order in the A β O's, the central turn region provides a constricted environment at position 26, and represents a common region for peptide-peptide interaction. The level of spin-coupling in the sample was attenuated by preparing A β O's consisting of 75% native A β and 25% of the TOAC-substituted A β (A β O^{TOAC}). The EPR spectra of the PAL-treated A β O^{TOAC} are shown in Figure 7. The black trace in panel A shows the broad spectrum of the TOAC label within A β O, reflecting a local region of order and a close proximity to other TOAC labels. This indicates the central hairpin turn region facilitates self-interaction within the oligomer. In contrast, the EPR spectrum of the PMT301 PAL alone displays a narrow line shape owing to the rapid rotational motion of the free small molecule in solution (panel A, inset). Upon addition of PMT301 to A β O^{TOAC}, a composite spectrum is obtained (red trace in panel A). The effect of the PAL agent on the

isolated A β O^{TOAC} signal can be observed by subtracting the spectrum of free PMT301 from the composite A β O^{TOAC} + PMT301 spectrum to produce the resulting PAL-modified A β O^{TOAC} spectrum (green trace in panel A). Thus, by comparing the black trace to the green trace we are comparing the A β O central region dynamics before and after PMT301 treatment. The altered state of the TOAC can also be confirmed by comparing the experimental composite spectrum (red trace) to the calculated sum of the two samples alone (blue trace in panel A). For example, if the PAL had no effect on A β O dynamics, the red and the blue traces would be identical. Panels B and C show the comparative effects of each PAL on A β O^{TOAC}. Here, the untreated A β O^{TOAC} spectrum (black trace) is compared to the sample after the PAL-alone component was subtracted. Thus, comparing each sample to the untreated A β O (black trace) reveals the degree of alteration each PAL has on the oligomer's central region. These results show that PMT301, PMT303 and PMT402 are most effective in increasing the dynamics at position 26 of A β . This is a significant finding, as PALs provide the highest potency in protection against A β O toxicity. In contrast the PMT302 treated A β O spectrum (panel B, green trace) looks similar to control A β O (panel B, black trace). Remarkably, the compound with the lowest potency (PMT401), is not only incapable of increasing the local dynamics of the turn region but displays spin-spin interaction with the TOAC label. This is evident from the resulting inverted amplitude line shape following subtraction of the free PMT401 component from the composite A β O (panel C, red trace). This indicates PMT401 binds and maintains A β O in a stable conformation with its nitroxyl moiety close (<1 nm) to the vicinity of TOAC26.

The effect of the stilbene PALs on the protofibril A β O^{TOAC} was also explored (Figures 7D–F). Panels D–F show the results of similar measurements on the protofibril A β O (fA β O) sample. A comparison of A β O to fA β O is shown in the inset of panel D. fA β O displays a broader EPR spectrum than A β O (including a discernable strongly immobilized component), reflecting the increased order and spin coupling found in the protofibril sample (Petrlova et al., 2012). The PALs have a similar, though smaller effect on fA β O. Thus, although CD reveals that PALs are unable to reverse the beta structure in the protofibril species, with the exception of PMT401, they do affect the packing geometry about the central region of the peptide.


3.7 Nanoparticle Tracking Analysis Measurements of Amyloid Beta Oligomers Treated With Each Stilbene PAL Candidate

We examined A β O preparations by Nanoparticle Tracking Analysis (NTA). NTA utilizes the properties of both light scattering and Brownian motion in order to obtain the nanoparticle size distribution of samples in liquid suspension. Briefly, 9–18 videos of 30 s duration per each sample were acquired, with a frame rate of 30 frames per second. The NTA software is optimized to first identify and subsequently track each particle on a frame-by-frame basis. The velocity of particle movement is used to calculate particle size by employing the



two-dimensional Stokes-Einstein equation. Given the relatively low refractive index of protein/peptide species, the smallest detectable size using the NTA system is roughly in the order of 70 nm. Since volume of the sample chamber is known and the NTA is essentially a single-nanoparticle detection system whereby each detected particle in the field of view over the duration of the recorded videos is calculated, the instrument also yields concentration data as particles per milliliter (part/ml). Thus, the data consists of particle concentration on the ordinate (y, part/ml) as the function of detected particle size on the abscissa (x, nm). The A β O prep is expected to generate a broad range of sizes (Hepler et al., 2006; Corsale et al., 2012), ranging from oligomers of 50–200 kD to much larger

amylospheroid and protofibrils, which do not migrate through size exclusion. For these measurements, stoichiometric amounts of PALs were added to preformed A β Os. The NTA results shown in **Figure 8A** indicate that the PAL compounds do not dramatically change the observed particle size, however each PAL generates a distinct distribution. There is a moderate correlation between the width of the major distribution peak to neuronal protection, with a narrower distribution favoring better protection. For example, the full-width at half maximal value (FWHM) of the distributions to potency of neuronal protection, with two of the more potent PALs (PMT-303 and PMT-402) having FWHM values ~45% lower than the other agents (**Table 2**). A major advantage of the NTA measurements is




their ability to quantify the particle concentration. As shown in **Table 2**, each of the PALs increases the population (relative to the untreated control) of oligomers into the NTA observable regime. Thus, a depletion of the smaller more toxic oligomers may constitute a part of the PALs' protective mechanism.

The NTA size distribution data is essentially spectral data whereby different peaks point out the predominant particle sizes in the measured solution. However, it is rather tedious to distinguish the prevalent sizes the different A β O + stilbene PAL combinations yield by only visually inspecting the size distribution charts. Therefore, we implemented a principal component analysis (PCA) in order to unveil whether there were certain trends in the observed particle sizes and if these trends potentially correlate with other measurements of PAL-induced structural adaptation. Briefly, PCA is a dimensionality reduction technique for multivariate data sets to simultaneously capture as much variability as possible and conserve the pertinent information responsible for the major sources of variability (Abdi and Williams, 2010). Analysis of the NTA results reveals that 86.5% of the total variance is captured using two principal components (PC1 and PC2). **Figure 8B** displays the 2-dimensional PC score plot that highlights the magnitude of variance and groupings within the NTA size distribution

TABLE 1 | Results from the fitting of the CD spectra by the BeStSel algorithm to estimate fractions of secondary structure in A β samples.

Species	A β O						Protofibril A β					
	cnt	301	302	303	401	402	Cnt	301	302	303	401	402
α	0	4.5	2.6	2.8	7.2	2.8	1.9	0	0	0	0	0
β	40.9	34.6	38.6	35.2	30.4	35.0	50.3	57.0	57.2	60.6	57.1	57.3
Turn	14.4	15.6	14.7	15.0	15.7	15.4	10.6	9.6	10.3	11.3	10.7	10.7
Other	44.7	45.3	44.2	47.0	47.1	46.7	37.2	33.4	32.5	28.1	32.1	32.1






FIGURE 7 | EPR spectra showing the how PALs alter the order within A β O. Shown are X-band EPR spectra of A β O^{TOAC} with and without PAL treatment. The black trace in panel **(A)** shows the broad spectrum of the TOAC label within A β O, reflecting a local region of order and a close proximity to other TOAC labels. In contrast, the EPR spectrum of the PMT301 PAL alone displays a narrow line shape owing to the rapid rotational motion of the free small molecule in solution [(A), inset]. Upon addition of PMT301 to A β O, a composite spectrum is obtained [red trace in (A)]. The effect of the PAL agent on the isolated A β O signal can be observed by subtracting the spectrum of free PMT301 from the composite A β O + PMT301 spectrum to produce the resulting PAL-modified A β O spectrum [green trace in (A)]. The increased amplitude of the green spectrum in panel A reflects a decrease in the TOAC spin label order following PMT301 treatment. The conformational effect of PMT301 is also evident when comparing the experimental composite spectrum (red trace) to the calculated sum of the two samples alone [blue trace in panel (A)]. **(B,C)** show the comparative effects of each PAL on A β O. In **(B,C)** the untreated A β O spectrum (black trace) is compared to the sample after subtraction of the PAL-alone (free PAL) component. **(D–F)** show the results of similar measurements on the protofibril A β O (fA β O) sample. A comparison of A β O to fA β O is shown in the inset of **(D)**. fA β O displays a broader EPR spectrum than A β O, reflecting the increased order and spin coupling found in the protofibril sample. Notably, subtraction of the free PMT401 component from the composite A β O and fA β O spectra results in spectra with inverted amplitudes [red traces in **(C,F)**]. This finding reveals evidence of spin coupling between the PMT401 nitroxyl moiety and the TOAC label on A β (i.e., the PMT401 contribution is substantially broadened in both the composite A β O + 401 spectrum and fA β O + 401 spectrum). Except for the inset spectra in **(A,D)**, spectral intensities represent stoichiometric amounts of A β O^{TOAC} and PAL agent (both at 80 μ M). The spectral amplitudes of each panel are normalized to the same amount of A β O^{TOAC}, and all spectra were collected over 100 G [field sweep axis displayed in **(E)**].

data. One single marker in the 2D score plot represents an average of 3 independent size distribution measurements by NTA. Thus, for instance the A β O only group comprises the data from 18 independent NTA measurements. Collectively both PC1 and PC2 loading spectra produce peaks that encapsulate the majority of variance within the NTA size distribution data.

Intriguingly, each stilbene PAL group is clearly distinguished from the A β O alone group (red markers), except the A β O + PMT-401 (green markers) group. This feature indicates that each stilbene PAL treatment influences the A β O size distribution to some extent, although PMT-401 treatment produces very similar size distribution profile with the A β O




TABLE 2 | Calculated particle parameters from NTA analysis of A β O samples.

Specimen	Average size (nm)	Mode size (nm)	Conc (part/ml)	195–595 nm fraction (%)	FWHM
ABO Only	159.2 \pm 1.5	127.9 \pm 3.3	1.59 \pm 10 ⁹ \pm 3.70 \pm 10 ⁷	20.3	76.58
ABO + PMT-401	161.8 \pm 1.9	124.1 \pm 6.3	2.07 \pm 10 ⁹ \pm 9.12 \pm 10 ⁸	23.7	90.44
ABO + PMT-402	145.9 \pm 2.2	116.7 \pm 3.7	3.40 \pm 10 ⁹ \pm 1.10 \pm 10 ⁸	28.7	71.32
ABO + PMT-301	164.9 \pm 1.3	129.7 \pm 4.7	4.84 \pm 10 ⁹ \pm 1.47 \pm 10 ⁸	26.0	104.39
ABO + PMT-302	166.0 \pm 2.5	134.5 \pm 2.9	4.23 \pm 10 ⁹ \pm 1.74 \pm 10 ⁸	28.4	98.64
ABO + PMT-303	155.6 \pm 3.8	133.8 \pm 5.5	2.56 \pm 10 ⁹ \pm 6.82 \pm 10 ⁷	17.0	68.63

alone group (the red and green groups highly overlapping). This result aligns with our other measurements showing the comparably poor characteristics of PMT-401 in A β O modulation. Furthermore, A β O treated with PMT-402 (blue markers) is the most discernible group from the others, which is also consistent with our other analyses. The 301–303 candidates not only differentiate from untreated A β O, but also from each other, with a slight overlapping of the A β O + PMT-301 (black markers) and A β O + PMT-302 (magenta markers) groups. The A β O + PMT-303 group (cyan markers) is noticeably tight compared to the others reflecting a significantly low internal variation.

As the PC1 and PC2 loading spectra are investigated, PMT-301, PMT-302 and PMT-402 have mostly positive score values along the PC1 axis of the score plot, corresponding to their intensities at 115 and 145 nm. Therefore, it is evident that these PALs produce more A β O of approximate diameter of 115 and 145 nm than A β -alone, PMT-401, and PMT-303. Moreover, the PMT-402 group has markedly positive scores along the PC2 axis, and the corresponding PC2 loading spectrum possesses a prominent positive peak at 105 nm. This is indicative of PMT-402 also generating a subpopulation of 105 nm particulates. On the other hand, the majority of PMT-301 and PMT-302 measurements have negative score values along the PC2 axis,

and the PC2 loading spectrum displays two negative peaks at 125–135 and 185 nm region. Taken together, PMT-301 and PMT-302 yield more particles of these sizes more than the other stilbenes.

4 DISCUSSION

In aqueous solution, A β forms a large size and conformational distribution that is highly influenced by its method of preparation (Teplow, 2006). Soluble A β can assume multiple states, with various oligomeric states implicated in different aspects of AD pathogenesis (Lesné et al., 2006; Amar et al., 2017; De et al., 2019). However, the correlation of a specific oligomeric size to a specific cellular target is difficult to establish, as very large assemblies can be overlooked in sieving methods and the dynamic nature of A β O makes its state highly sensitive to reagent and matrix influences (Hepler et al., 2006; Hubin et al., 2014). A general consensus across studies points to intermediate-sized (>50 kDa), A11-positive oligomers inducing the broadest range of neuronal toxicity and dysfunction (Vandersteen et al., 2012; Cline et al., 2018). We therefore employed a simple prep that produces A11-positive, neurotoxic oligomers, and can likewise reproducibly transition into a soluble protofibril species. These oligomers retain a significant amount of conformational heterogeneity and ~40% beta sheet content (Sandberg et al., 2010; Vandersteen et al., 2012; Roy et al., 2017).

Our previous reports on a fluorene-based PAL compound demonstrated its high potency is related to the localization of nitroxide antioxidant activity within the cell, interrupting the cycle of ROS-enhanced A β O cytotoxicity and accumulation (Petrlova et al., 2012; Altman et al., 2015; Hilt et al., 2018). The high antioxidant potency of the nitroxide can be attributed its ability to cycle through alternate redox states, mimicking the antioxidant defense of superoxide dismutase (SOD) (Hideg and Kálai, 2007; Mandal et al., 2007). In cells, the redox cycle for a nitroxide begins with the reduction of the N-O state to the N-OH state, which can be re-oxidized to N-O by ROS. Likewise, hydroxyl and peroxy radicals can oxidize the N-O state to the nitron (N=O), which is then available to remove superoxide and regenerate the N-O state. Subsequent reduction (e.g., by GSH) to N-OH allows for a single nitroxide to perform several rounds of scavenging. Importantly the N-oxyl (nitroxyl) is not oxidative to other biomolecules (lipids, proteins, DNA). Consistent with previous studies of a fluorene-based PAL, the synergistic activity of stilbene PALs provides a potency 10–500 times greater than other anti-amyloid small molecules such as SEN1269 (Scopes et al., 2012) and resveratrol (Marambaud et al., 2005).

The antioxidant activity of the PALs is exemplified by the strong attenuation of the CellROX signal in MC65 cells induced for C99 expression. This potency is significant for two reasons: 1) brain bioavailability is a challenge for nearly all agents targeting amyloid-like proteins, and 2) it facilitates a targeted mechanism for countering oxidative stress, which is important as high antioxidant doses can become prooxidants, down-regulate

endogenous antioxidant pathways and interfere with beneficial ROS/RNS-dependent signaling (Bouayed and Bohn, 2010).

Because each of the stilbene PAL agents contain a similar nitroxyl moiety, their effects on A β O conformation and assembly can point to structures that are superior in A β O engagement and/or remodeling. However, caveats remain, such as differences in the availability of free compound to the cell interior (e.g., differences in permeation, off-target protein binding). In terms of bioactivity and various metrics of A β O engagement, the aminostilbene PMT-402 displays the highest potency. In contrast, the aminostilbene PMT-401 shows the lowest potency. Although care was taken to maximize compound dispersion in all assays, the markedly lower solubility of PMT-401 could lower its effective concentration in our measurements.

Recognition of oligomer species by the A11 antibody provides a basis for identifying conformational toxicity, as it reacts against a diverse set of protein aggregates known to trigger neurodegeneration (Kayed et al., 2003). As described previously (Necula et al., 2007), attenuation of A11 binding can help identify compounds that convert A β O towards a less toxic conformation. Each of the 5 stilbene PALs significantly reduce A11 binding to A β O. The results suggest PMT-402 is most potent in this regard, however the variability inherent to the assay precludes ranking the other PAL agents according to potency. The reduction in binding may reflect an allosteric transition of the peptide away from its A11-positive conformation, although PAL occupation of the A11 epitope is also possible.

The CD spectrum of the aqueous A β O sample prior to its 1-h incubation displays a relatively flat, low amplitude signal (not shown) that increase in β -sheet content with time (Clements et al., 1996; Shea et al., 2019). This characteristic signal has been attributed to the peptide in the extended α -sheet, a conformation predicted to populate “toxic” soluble oligomers that ultimately mature into amyloid fibrils (Hayward and Milner-White, 2008; Babin et al., 2011; Hopping et al., 2014; Shea et al., 2019). After 1-h of incubation, the CD spectrum of the A β oligomers used in this study indicates the major fraction of secondary structure falls within the “disordered” portion of the spectra, however non-random conformations such as the extended poly-proline-II (PPII)-like helix also contribute intensities in this regime (i.e., a band with defined minimum in the 195–200 nm) (Gokce et al., 2005; Sandberg et al., 2010; Nisbet et al., 2013).

Deconvolution of the CD spectra for secondary structure composition indicates that PAL treatment of A β O with PALs in general results in a slight reduction in β -strand and corresponding increase in the helical component, with the major spectral change occurring within the regime classified as “other.” The most significant effect is, with the exception of PMT-401, is the generation of a polyproline II (PPII)-like spectral intensity (Adzhubei et al., 2013). A similar result has been observed when treating A β O with a fluorene-based PAL (Altman et al., 2015), or examining the peptide at low temperature (Danielsson et al., 2005). Both the α -sheet and PP-II configurations display exposed backbone carbonyls, which have been postulated to drive protein-protein interactions (Fernández and Crespo, 2008; Hayward and Milner-White, 2008; Theillet et al., 2013; Adzhubei et al., 2017), readily convert to β -strand (Blanch et al., 2000; Hayward and Milner-White,

2008; Adzhubei et al., 2017), and have been proposed to illicit “toxic” conformations (Blanch et al., 2000; Shea et al., 2019). With respect to these populations within A β O, the CD results are consistent with a decrease in the fraction of α -sheet structure for the bioactive PALs.

We also examined the effect of the stilbene PALs on the CD spectrum of protofibril oligomers formed after 24-h incubation. These species display significantly more order with a high fraction of β -sheet secondary structure (Kayad et al., 2009). A far less dramatic alteration of the CD spectrum is observed with PAL treatment of protofibrils, although each of the compounds increase β -sheet content and decrease disordered content. With protofibrils showing low cytotoxicity, the absence of their disruption by the stilbene PALs can be viewed as a favorable property.

With respect to dye binding, compared to ThT, changes in NR fluorescence intensity appear to provide a better predictive value for the potency in the MC65 assay. In contrast to the CD measurements PMT-402 is not distinguished in either dye assay. Each of the PAL agents provide a strong inhibition of β -sheet formation as determined by ThT. However, the NR assay reports a differential effect with PMT-302, with the compound producing increased NR solvent exposure. Thus, the ability of PALs to occlude hydrophobic patches within A β O may provide a useful metric in identifying candidates to protect against A β O toxicity.

As shown in previous studies (Petrlova et al., 2012; Altman et al., 2015), EPR analyses of both A β O^{TOAC} and protofibril A β O^{TOAC} demonstrate that the TOAC spin label at position 26 reflects a moderate degree of order within the oligomer. Although the TOAC label is diluted with the oligomer to minimize spin-spin interaction, dipolar interactions between labels in close (~1.5 nm) proximity also contribute to the spectral broadening. Thus, we cannot attribute increased motional freedom as the only source behind the PAL-induced effects onto the A β O^{TOAC} and protofibrils (Petrlova et al., 2012; Altman et al., 2015). In any event, both an increase in the spin label correlation time and decreased dipolar coupling are indicative of oligomer remodeling. PMT-301 and PMT-303 induce the largest effects on the EPR spectrum of A β O^{TOAC}, while PMT-402 had the greatest effect in the protofibril A β O^{TOAC} sample. Interestingly, PMT-401 showed no ability to alter the structure around the TOAC spin label. Therefore, EPR spectral changes reported by the TOAC label at position 26 may also be predictive for active candidates in the MC65 assay. Furthermore, the subtraction of the free PAL component from the PMT-401 treated A β O^{TOAC} results in a negative spectral line. This can be explained if the PMT-401 contribution to the composite sample is broadened *via* dipolar coupling. Thus, PMT-401 may uniquely position its nitroxyl moiety in close proximity position 26 of the A β O^{TOAC} sample. Finally, the EPR results again identified PMT-302 and PMT-401 as the least consequential PALs, showing a general agreement among the bioactivity, CD and dye binding results.

While the explicit molecular level mechanisms on how the stilbene PALs give rise to specimens of different sizes remain to be solved, the NTA-PCA analysis reveals some noteworthy aspects. First, PMT-401 (least effective in bioactivity) most resembles the untreated A β O; and PMT-402 (most effective in bioactivity) is the most distinguished in the PCA plot. Also, the

FWHM feature of the distribution curve is somewhat predictive (Table 2), with PMT-402 and PMT-303 showing the lowest values (the high FWHM value of PMT-301 – intermediate bioactivity – suggests this metric may not serve as predictive in all cases). Second, with the exception of PMT-401, all the stilbene PAL modulators yield unique size distribution profiles that are markedly different from the A β O-alone sample and across each other as well. Therefore, the neural cell protective nature of the potent stilbene PALs may at least partially be explained by their capability to either 1) dislodge very large A β O and protofibrils (>200 nm) into smaller particulates (105–145 nm), 2) assemble smaller toxic A β O (oligomers of 50–200 kD) into larger entities (105–145 nm), or 3) stabilize the existing less-toxic A β O in the approximate size range of 105–145 nm. We cautiously hypothesize that whichever is the mechanism, the ultimate benefit is to generate A β O of suitable size that are more easily dispatched from the cells. However, these hypotheses warrant for further targeted studies that were out of the scope of this study.

The amyloid-independent anti-inflammatory activity on HBMECs challenged by TGRL lipolysis products (TL) provides insights as to whether the antioxidant activity of the stilbene PALs can reduce inflammation on a more general basis. Only PMT-401 significantly suppressed TL-induced expression of all measured cytokines as well as COX-2 gene expression. Because PMT-401 is significantly more hydrophobic than the other PALs, effective downregulation of inflammation in the HBMEC model requires is likely dependent on the agent's partition into lipophilic domains. The other PALs did not suppress cytokine gene expression, however PMT-302 and PMT-303 did significantly suppress TL-induced COX-2 expression.

The fact that the secondary structure of the PAL-treated A β O remains largely disordered implies that shifting the equilibrium away from the toxic conformer may only require the modulation of a discrete structural feature within the ensemble. As the clinical quantification of AD risk *via* early biomarkers becomes a reality, small molecules are practical for continuous treatment to maintain a favorable balance of A β species (with respect to toxicity cellular clearance) in patients. This concept is similar to the administration of statins in cardiovascular health. In this regard, describing the interaction of our distinct PAL agents as a function of conformational toxicity will aid future development of small molecule structural correctors.

Developing small molecules with bifunctionality provides meaningful advantages as potential clinical applications are considered. Because *in vivo* safety and efficacy testing (e.g., tolerance, pharmacokinetics, pharmacodynamics) are carried out for single agents, there is a growing interest in developing compounds to address more than one target (Corson et al., 2008; Bachurin et al., 2017; Ramsay et al., 2018). The bi-functional approach provides synergistic action on two pathogenetic hallmarks of the disease resulting in considerable enhancement of the overall pharmacological effect and may provide both cognition-stimulating and disease-modifying actions.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Human Subjects Review Committee/IRB at the University of California, Davis.

AUTHOR CONTRIBUTIONS

JV directed the study (lead on collection, interpretation, writing). SH collected bioactivity data and edited paper, RS collected dye binding data, MB collected EPR data, TR collected and analyzed NTA data, RC supervised NTA experiments and edited paper, HA collected and analyzed cytokine data, QG helped with confocal data, IM collected cell protection data, RL designed and synthesized the PAL compounds and wrote the chemistry portion of the paper.

REFERENCES

- Abdi, H., and Williams, L. J. (2010). Principal Component Analysis. *WIREs Comp. Stat.* 2 (4), 433–459. doi:10.1002/wics.101
- Adzhubei, A. A., Anashkina, A. A., and Makarov, A. A. (2017). Left-handed Polyproline-II Helix Revisited: Proteins Causing Proteopathies. *J. Biomol. Struct. Dyn.* 35 (12), 2701–2713. doi:10.1080/07391102.2016.1229220
- Adzhubei, A. A., Sternberg, M. J. E., and Makarov, A. A. (2013). Polyproline-II Helix in Proteins: Structure and Function. *J. Mol. Biol.* 425 (12), 2100–2132. doi:10.1016/j.jmb.2013.03.018
- Ahmed, T., Javed, S., Javed, S., Tariq, A., Šamec, D., Tejada, S., et al. (2017). Resveratrol and Alzheimer's Disease: Mechanistic Insights. *Mol. Neurobiol.* 54 (4), 2622–2635. doi:10.1007/s12035-016-9839-9
- Almeida, L., Vaz-da-Silva, M., Falcão, A., Soares, E., Costa, R., Loureiro, A. I., et al. (2009). Pharmacokinetic and Safety Profile of Trans-resveratrol in a Rising Multiple-Dose Study in Healthy Volunteers. *Mol. Nutr. Food Res.* 53 (Suppl. 1), S7–S15. doi:10.1002/mnfr.200800177
- Altman, R., Ly, S., Hilt, S., Petrlova, J., Maezawa, I., Kálai, T., et al. (2015). Protective Spin-Labeled Fluorenes Maintain Amyloid Beta Peptide in Small Oligomers and Limit Transitions in Secondary Structure. *Biochimica Biophysica Acta (BBA) - Proteins Proteomics* 1854 (12), 1860–1870. doi:10.1016/j.bbapap.2015.09.002
- Amar, F., Sherman, M. A., Rush, T., Larson, M., Boyle, G., Chang, L., et al. (2017). The Amyloid- β Oligomer A β *56 Induces Specific Alterations in Neuronal Signaling that Lead to Tau Phosphorylation and Aggregation. *Sci. Signal.* 10 (478), eaal2021. doi:10.1126/scisignal.aal2021
- Aung, H. H., Altman, R., Nyunt, T., Kim, J., Nuthikattu, S., Budamagunta, M., et al. (2016). Lipotoxic Brain Microvascular Injury Is Mediated by Activating Transcription Factor 3-dependent Inflammatory and Oxidative Stress Pathways. *J. Lipid Res.* 57 (6), 955–968. doi:10.1194/jlr.M061853
- Aung, H. H., Lame, M. W., Gohil, K., An, C.-I., Wilson, D. W., and Rutledge, J. C. (2013). Induction of ATF3 Gene Network by Triglyceride-Rich Lipoprotein Lipolysis Products Increases Vascular Apoptosis and Inflammation. *Arterioscler. Thromb. Vasc. Biol.* 33 (9), 2088–2096. doi:10.1161/ATVBAHA.113.301375
- Aung, H. H., Tsoukalas, A., Rutledge, J. C., and Tagkopoulos, I. (2014). A Systems Biology Analysis of Brain Microvascular Endothelial Cell Lipotoxicity. *BMC Syst. Biol.* 8, 80. doi:10.1186/1752-0509-8-80
- Babin, V., Roland, C., and Sagui, C. (2011). The α -sheet: A Missing-In-Action Secondary Structure? *Proteins* 79 (3), 937–946. doi:10.1002/prot.22935
- Bachurin, S. O., Shevtsova, E. F., Makhaeva, G. F., Grigoriev, V. V., Boltneva, N. P., Kovaleva, N. V., et al. (2017). Novel Conjugates of Aminoadamantanes with Carbazole Derivatives as Potential Multitarget Agents for AD Treatment. *Sci. Rep.* 7, 45627. doi:10.1038/srep45627
- Bartolini, M., Bertucci, C., Bolognesi, M. L., Cavalli, A., Melchiorre, C., and Andrisano, V. (2007). Insight into the Kinetic of Amyloid β (1–42) Peptide Self-Aggregation: Elucidation of Inhibitors' Mechanism of Action. *ChemBioChem* 8 (17), 2152–2161. doi:10.1002/cbic.200700427
- Bieschke, J., Herbst, M., Wiglenda, T., Friedrich, R. P., Boeddrich, A., Schiele, F., et al. (2011). Small-molecule Conversion of Toxic Oligomers to Nontoxic β -sheet-rich Amyloid Fibrils. *Nat. Chem. Biol.* 8 (1), 93–101. doi:10.1038/nchembio.719
- Blanch, E. W., Morozova-Roche, L. A., Cochran, D. A. E., Doig, A. J., Hecht, L., and Barron, L. D. (2000). Is Polyproline II Helix the Killer Conformation? a Raman Optical Activity Study of the Amyloidogenic Prefibrillar Intermediate of Human Lysozyme 1 | Edited by A. R. Fersht. *J. Mol. Biol.* 301 (2), 553–563. doi:10.1006/jmbi.2000.3981
- Bloom, G. S. (2014). Amyloid- β and Tau. *JAMA Neurol.* 71 (4), 505–508. doi:10.1001/jamaneurol.2013.5847
- Bonda, D. J., Wang, X., Perry, G., Nunomura, A., Tabatou, M., Zhu, X., et al. (2010). Oxidative Stress in Alzheimer Disease: a Possibility for Prevention. *Neuropharmacology* 59 (4–5), 290–294. doi:10.1016/j.neuropharm.2010.04.005
- Bouayed, J., and Bohn, T. (2010). Exogenous Antioxidants—Double-Edged Swords in Cellular Redox State: Health Beneficial Effects at Physiologic Doses versus Deleterious Effects at High Doses. *Oxidative Med. Cell. Longev.* 3 (4), 228–237. doi:10.4161/oxim.3.4.12858
- Brouillette, J., Caillierez, R., Zommer, N., Alves-Pires, C., Benilova, I., Blum, D., et al. (2012). Neurotoxicity and Memory Deficits Induced by Soluble Low-Molecular-Weight Amyloid-1–42 Oligomers Are Revealed *In Vivo* by Using a Novel Animal Model. *J. Neurosci.* 32 (23), 7852–7861. doi:10.1523/JNEUROSCI.5901-11.2012

FUNDING

This work was supported by a STAIR Award from the University of California, Davis to JV, and in part with funding from the National Institutes of Health (grant P30 AG010129 to JV). SH was supported by the NIH Post-doctoral Neuroscience of Cognitive Aging Training Program (NoCA-T32).

ACKNOWLEDGMENTS

HA acknowledges support from the Packer Wizard Foundation. The authors would like to thank the Combinatorial Chemistry and Chemical Biology Shared Resource at University of California, Davis for its assistance with the synthesis of PAL compounds.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fchem.2022.896386/full#supplementary-material>

- Capiralla, H., Vingtdoux, V., Zhao, H., Sankowski, R., Al-Abed, Y., Davies, P., et al. (2012). Resveratrol Mitigates Lipopolysaccharide- and A β -Mediated Microglial Inflammation by Inhibiting the TLR4/NF-K β /STAT Signaling Cascade. *J. Neurochem.* 120 (3), 461–472. doi:10.1111/j.1471-4159.2011.07594.x
- Chunhui, H., Dilin, X., Ke, Z., Jieyi, S., Sicheng, Y., Dapeng, W., et al. (2018). A11-positive β -amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis. *J. Vis. Exp.* 135. doi:10.3791/57592
- Clements, A., Allsop, D., Walsh, D. M., and Williams, C. H. (1996). Aggregation and Metal-Binding Properties of Mutant Forms of the Amyloid A β Peptide of Alzheimer's Disease. *J. Neurochem.* 66 (2), 740–747. doi:10.1046/j.1471-4159.1996.66020740.x
- Cline, E. N., Bicca, M. A., Viola, K. L., and Klein, W. L. (2018). The Amyloid- β Oligomer Hypothesis: Beginning of the Third Decade. *Jad* 64 (s1), S567–S610. doi:10.3233/JAD-179941
- Colom-Cadena, M., Gelpi, E., Charif, S., Belbin, O., Blesa, R., Martí, M. J., et al. (2013). Confluence of α -Synuclein, Tau, and β -Amyloid Pathologies in Dementia with Lewy Bodies. *J. Neuropathol. Exp. Neurol.* 72 (12), 1203–1212. doi:10.1097/NEN.000000000000018
- Copenhaver, P. F., Anekonda, T. S., Musashe, D., Robinson, K. M., Ramaker, J. M., Swanson, T. L., et al. (2011). A Translational Continuum of Model Systems for Evaluating Treatment Strategies in Alzheimer's Disease: Isradipine as a Candidate Drug. *Dis. Model Mech.* 4 (5), 634–648. doi:10.1242/dmm.006841
- Corsale, C., Carrotta, R., Mangione, M. R., Vilasi, S., Provenzano, A., Cavallaro, G., et al. (2012). Entrapment of A β 1–40peptide in Unstructured Aggregates. *J. Phys. Condens. Matter* 24 (24), 244103. doi:10.1088/0953-8984/24/24/244103
- Corson, T. W., Aberle, N., and Crews, C. M. (2008). Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One. *ACS Chem. Biol.* 3 (11), 677–692. doi:10.1021/cb800179z
- Cottart, C.-H., Nivet-Antoine, V., Laguillier-Morizot, C., and Beaudeau, J.-L. (2010). Resveratrol Bioavailability and Toxicity in Humans. *Mol. Nutr. Food Res.* 54 (1), 7–16. doi:10.1002/mnfr.200900437
- Currais, A., Quehenberger, O., Armando, A. M., Daugherty, D., Maher, P., and Schubert, D. (2016). Amyloid Proteotoxicity Initiates an Inflammatory Response Blocked by Cannabinoids. *NPJ Aging Mech. Dis.* 2, 16012. doi:10.1038/nnpjamd.2016.12
- Danielsson, J., Jarvet, J., Damberg, P., and Gräslund, A. (2005). The Alzheimer β -peptide Shows Temperature-dependent Transitions between Left-Handed 31-helix, β -strand and Random Coil Secondary Structures. *FEBS J.* 272 (15), 3938–3949. doi:10.1111/j.1742-4658.2005.04812.x
- De, S., Wirthensohn, D. C., Flagmeier, P., Hughes, C., Aprile, F. A., Ruggeri, F. S., et al. (2019). Different Soluble Aggregates of A β 42 Can Give Rise to Cellular Toxicity through Different Mechanisms. *Nat. Commun.* 10 (1), 1541. doi:10.1038/s41467-019-09477-3
- Drygalski, K., Fereniec, E., Koryciński, K., Chomentowski, A., Kielczewska, A., Odrzygóźdź, C., et al. (2018). Resveratrol and Alzheimer's Disease. From Molecular Pathophysiology to Clinical Trials. *Exp. Gerontol.* 113, 36–47. doi:10.1016/j.exger.2018.09.019
- Dunning, C. J., McGauran, G., Willén, K., Gouras, G. K., O'Connell, D. J., and Linse, S. (2016). Direct High Affinity Interaction between A β 42 and GSK3 α Stimulates Hyperphosphorylation of Tau. A New Molecular Link in Alzheimer's Disease? *ACS Chem. Neurosci.* 7 (2), 161–170. doi:10.1021/acchemneuro.5b00262
- Dutta, S., Foley, A. R., Warner, C. J. A., Zhang, X., Rolandi, M., Abrams, B., et al. (2017). Suppression of Oligomer Formation and Formation of Non-toxic Fibrils upon Addition of Mirror-Image A β 42 to the Natural L-Enantiomer. *Angew. Chem. Int. Ed.* 56 (38), 11506–11510. doi:10.1002/anie.201706279
- Feng, Y., Wang, X.-p., Yang, S.-g., Wang, Y.-j., Zhang, X., Du, X.-t., et al. (2009). Resveratrol Inhibits Beta-Amyloid Oligomeric Cytotoxicity but Does Not Prevent Oligomer Formation. *Neurotoxicology* 30 (6), 986–995. doi:10.1016/j.neuro.2009.08.013
- Fernández, A., and Crespo, A. (2008). Protein Wrapping: a Molecular Marker for Association, Aggregation and Drug Design. *Chem. Soc. Rev.* 37 (11), 2373–2382. doi:10.1039/b804150b
- Fezoui, Y., and Teplow, D. B. (2002). Kinetic Studies of Amyloid β -Protein Fibril Assembly. *J. Biol. Chem.* 277 (40), 36948–36954. doi:10.1074/jbc.M204168200
- Figueiredo, C. P., Clarke, J. R., Ledo, J. H., Ribeiro, F. C., Costa, C. V., Melo, H. M., et al. (2013). Memantine Rescues Transient Cognitive Impairment Caused by High-Molecular-Weight A Oligomers but Not the Persistent Impairment Induced by Low-Molecular-Weight Oligomers. *J. Neurosci.* 33 (23), 9626–9634. doi:10.1523/JNEUROSCI.0482-13.2013
- Fu, Z., Aucoin, D., Ahmed, M., Zilio, M., Van Nostrand, W. E., and Smith, S. O. (2014). Capping of A β 42 Oligomers by Small Molecule Inhibitors. *Biochemistry* 53 (50), 7893–7903. doi:10.1021/bi500910b
- Ge, J.-F., Qiao, J.-P., Qi, C.-C., Wang, C.-W., and Zhou, J.-N. (2012). The Binding of Resveratrol to Monomer and Fibril Amyloid Beta. *Neurochem. Int.* 61 (7), 1192–1201. doi:10.1016/j.neuint.2012.08.012
- Gokce, I., Woody, R. W., Anderlueh, G., and Lakey, J. H. (2005). Single Peptide Bonds Exhibit Poly(pro)II ("random Coil") Circular Dichroism Spectra. *J. Am. Chem. Soc.* 127 (27), 9700–9701. doi:10.1021/ja052632x
- Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., et al. (2003). Alzheimer's Disease-Affected Brain: Presence of Oligomeric A β Ligands (ADDLs) Suggests a Molecular Basis for Reversible Memory Loss. *Proc. Natl. Acad. Sci. U.S.A.* 100 (18), 10417–10422. doi:10.1073/pnas.1834302100
- Guerrero-Muñoz, M. J., Castillo-Carranza, D. L., and Kaye, R. (2014). Therapeutic Approaches against Common Structural Features of Toxic Oligomers Shared by Multiple Amyloidogenic Proteins. *Biochem. Pharmacol.* 88 (4), 468–478. doi:10.1016/j.bcp.2013.12.023
- Haass, C., and Selkoe, D. J. (2007). Soluble Protein Oligomers in Neurodegeneration: Lessons from the Alzheimer's Amyloid β -peptide. *Nat. Rev. Mol. Cell Biol.* 8 (2), 101–112. doi:10.1038/nrm2101
- Hayward, S., and Milner-White, E. J. (2008). The Geometry of α -sheet: Implications for its Possible Function as Amyloid Precursor in Proteins. *Proteins* 71 (1), 415–425. doi:10.1002/prot.21717
- Hellstrand, E., Boland, B., Walsh, D. M., and Linse, S. (2010). Amyloid β -Protein Aggregation Produces Highly Reproducible Kinetic Data and Occurs by a Two-phase Process. *ACS Chem. Neurosci.* 1, 13–18. doi:10.1021/cn900015v
- Hepler, R. W., Grimm, K. M., Nahas, D. D., Breese, R., Dodson, E. C., Acton, P., et al. (2006). Solution State Characterization of Amyloid β -Derived Diffusible Ligands. *Biochemistry* 45 (51), 15157–15167. doi:10.1021/bi061850f
- Hideg, K., and Kálai, T. (2007). Novel Antioxidants in Anthracycline Cardiotoxicity. *Cardiovasc. Toxicol.* 7 (2), 160–164. doi:10.1007/s12012-007-0019-z
- Hilt, S., Altman, R., Kálai, T., Maezawa, I., Gong, Q., Wachsmann-Hogiu, S., et al. (2018). A Bifunctional Anti-amyloid Blocks Oxidative Stress and the Accumulation of Intraneuronal Amyloid-Beta. *Molecules* 23 (8), 2010. doi:10.3390/molecules23082010
- Hong, H.-S., Maezawa, I., Yao, N., Xu, B., Diaz-Avalos, R., Rana, S., et al. (2007). Combining the Rapid MTT Formazan Exocytosis Assay and the MC65 Protection Assay Led to the Discovery of Carbazole Analogs as Small Molecule Inhibitors of A β Oligomer-Induced Cytotoxicity. *Brain Res.* 1130 (1), 223–234. doi:10.1016/j.brainres.2006.10.093
- Hopping, G., Kellock, J., Barnwal, R. P., Law, P., Bryers, J., Varani, G., et al. (2014). Designed α -sheet Peptides Inhibit Amyloid Formation by Targeting Toxic Oligomers. *Elife* 3, e01681. doi:10.7554/eLife.01681
- Hubin, E., van Nuland, N. A. J., Broersen, K., and Pauwels, K. (2014). Transient Dynamics of A β Contribute to Toxicity in Alzheimer's Disease. *Cell. Mol. Life Sci.* 71 (18), 3507–3521. doi:10.1007/s00018-014-1634-z
- Jin, L.-W., Maezawa, I., Vincent, I., Bird, T., and Bird, T. (2004). Intracellular Accumulation of Amyloidogenic Fragments of Amyloid- β Precursor Protein in Neurons with Niemann-Pick Type C Defects Is Associated with Endosomal Abnormalities. *Am. J. Pathology* 164 (3), 975–985. doi:10.1016/s0002-9440(10)63185-9
- Jo, D.-G., Arumugam, T. V., Woo, H.-N., Park, J.-S., Tang, S.-C., Mughal, M., et al. (2010). Evidence that γ -secretase Mediates Oxidative Stress-Induced β -secretase Expression in Alzheimer's Disease. *Neurobiol. Aging* 31 (6), 917–925. doi:10.1016/j.neurobiolaging.2008.07.003
- Karuppagounder, S. S., Pinto, J. T., Xu, H., Chen, H.-L., Beal, M. F., and Gibson, G. E. (2009). Dietary Supplementation with Resveratrol Reduces Plaque Pathology in a Transgenic Model of Alzheimer's Disease. *Neurochem. Int.* 54 (2), 111–118. doi:10.1016/j.neuint.2008.10.008
- Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., et al. (2003). Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis. *Science* 300 (5618), 486–489. doi:10.1126/science.1079469

- Kayed, R., and Lasagna-Reeves, C. A. (2012). Molecular Mechanisms of Amyloid Oligomers Toxicity. *J. Alzheimers Dis.* 33 (Suppl. 1), S67–S78. doi:10.3233/JAD-2012-129001
- Kayed, R., Pensalfini, A., Margol, L., Sokolov, Y., Sarsoza, F., Head, E., et al. (2009). Annular Protofibrils Are a Structurally and Functionally Distinct Type of Amyloid Oligomer. *J. Biol. Chem.* 284 (7), 4230–4237. doi:10.1074/jbc.M808591200
- Kienlen-Campard, P., Miolet, S., Tasiaux, B., and Octave, J.-N. (2002). Intracellular Amyloid-B1-42, but Not Extracellular Soluble Amyloid- β Peptides, Induces Neuronal Apoptosis. *J. Biol. Chem.* 277 (18), 15666–15670. doi:10.1074/jbc.M200887200
- Knobloch, M., Konietzko, U., Krebs, D. C., and Nitsch, R. M. (2007). Intracellular A β and Cognitive Deficits Precede β -amyloid Deposition in Transgenic arcA β Mice. *Neurobiol. Aging* 28 (9), 1297–1306. doi:10.1016/j.neurobiolaging.2006.06.019
- Ladiwala, A. R. A., Lin, J. C., Bale, S. S., Marcelino-Cruz, A. M., Bhattacharya, M., Dordick, J. S., et al. (2010). Resveratrol Selectively Remodels Soluble Oligomers and Fibrils of Amyloid A β into Off-Pathway Conformers. *J. Biol. Chem.* 285 (31), 24228–24237. doi:10.1074/jbc.M110.133108
- Ladiwala, A. R. A., Litt, J., Kane, R. S., Aucoin, D. S., Smith, S. O., Ranjan, S., et al. (2012). Conformational Differences between Two Amyloid β Oligomers of Similar Size and Dissimilar Toxicity. *J. Biol. Chem.* 287 (29), 24765–24773. doi:10.1074/jbc.M111.329763
- Lesné, S., Koh, M. T., Kotilinek, L., Kaye, R., Glabe, C. G., Yang, A., et al. (2006). A Specific Amyloid- β Protein Assembly in the Brain Impairs Memory. *Nature* 440 (7082), 352–357. doi:10.1038/nature04533
- Limanaqi, F., Biagioni, F., Gambardella, S., Familiari, P., Frati, A., and Fornai, F. (2020). Promiscuous Roles of Autophagy and Proteasome in Neurodegenerative Proteinopathies. *Int. J. Mol. Sci.* 21 (8), 3028. doi:10.3390/ijms21083028
- Liu, Y.-H., Giunta, B., Zhou, H.-D., Tan, J., and Wang, Y.-J. (2012). Immunotherapy for Alzheimer Disease-The Challenge of Adverse Effects. *Nat. Rev. Neurol.* 8 (8), 465–469. doi:10.1038/nrneurol.2012.118
- Liu, Z., Zhou, T., Ziegler, A. C., Dimitrion, P., and Zuo, L. (2017). Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications. *Oxidative Med. Cell. Longev.* 2017, 1–11. doi:10.1155/2017/2525967
- Livak, K. J., and Schmittgen, T. D. (2001). Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2- $\Delta\Delta$ CT Method. *Methods* 25 (4), 402–408. doi:10.1006/meth.2001.1262
- Ma, T., Tan, M.-S., Yu, J.-T., and Tan, L. (2014). Resveratrol as a Therapeutic Agent for Alzheimer's Disease. *BioMed Res. Int.* 2014, 1–13. doi:10.1155/2014/350516
- Maccioni, R. B., Farias, G., Morales, I., and Navarrete, L. (2010). The Revitalized Tau Hypothesis on Alzheimer's Disease. *Archives Med. Res.* 41 (3), 226–231. doi:10.1016/j.arcmed.2010.03.007
- Maizawa, I., Hong, H. S., Liu, R., Wu, C. Y., Cheng, R. H., Kung, M. P., et al. (2008). Congo Red and Thioflavin-T Analogs Detect Abeta Oligomers. *J. Neurochem.* 104 (2), 457–468. doi:10.1111/j.1471-4159.2007.04972.x
- Maizawa, I., Hong, H.-S., Wu, H.-C., Battina, S. K., Rana, S., Iwamoto, T., et al. (2006). A Novel Tricyclic Pyrone Compound Ameliorates Cell Death Associated with Intracellular Amyloid-Beta Oligomeric Complexes. *J. Neurochem.* 98 (1), 57–67. doi:10.1111/j.1471-4159.2006.03862.x
- Mandal, R., Kutala, V. K., Khan, M., Mohan, I. K., Varadharaj, S., Sridhar, A., et al. (2007). N-hydroxy-pyrroline Modification of Verapamil Exhibits Antioxidant Protection of the Heart against Ischemia/reperfusion-Induced Cardiac Dysfunction without Compromising its Calcium Antagonistic Activity. *J. Pharmacol. Exp. Ther.* 323 (1), 119–127. doi:10.1124/jpet.107.127167
- Marambaud, P., Zhao, H., and Davies, P. (2005). Resveratrol Promotes Clearance of Alzheimer's Disease Amyloid- β Peptides. *J. Biol. Chem.* 280 (45), 37377–37382. doi:10.1074/jbc.M508246200
- Miconai, A., Wien, F., Keryna, L., Lee, Y.-H., Goto, Y., Réfrégiers, M., et al. (2015). Accurate Secondary Structure Prediction and Fold Recognition for Circular Dichroism Spectroscopy. *Proc. Natl. Acad. Sci. U.S.A.* 112 (24), E3095–E3103. doi:10.1073/pnas.1500851112
- Moussa, C., Hebron, M., Huang, X., Ahn, J., Rissman, R. A., Aisen, P. S., et al. (2017). Resveratrol Regulates Neuro-Inflammation and Induces Adaptive Immunity in Alzheimer's Disease. *J. Neuroinflammation* 14 (1), 1. doi:10.1186/s12974-016-0779-0
- Mputhia, Z., Hone, E., Tripathi, T., Sargeant, T., Martins, R., and Bharadwaj, P. (2019). Autophagy Modulation as a Treatment of Amyloid Diseases. *Molecules* 24 (18), 3372. doi:10.3390/molecules24183372
- Murakami, K. (2014). Conformation-specific Antibodies to Target Amyloid β Oligomers and Their Application to Immunotherapy for Alzheimer's Disease. *Biosci. Biotechnol. Biochem.* 78 (8), 1293–1305. doi:10.1080/09168451.2014.940275
- Necula, M., Kaye, R., Milton, S., and Glabe, C. G. (2007). Small Molecule Inhibitors of Aggregation Indicate that Amyloid β Oligomerization and Fibrillization Pathways Are Independent and Distinct. *J. Biol. Chem.* 282 (14), 10311–10324. doi:10.1074/jbc.M608207200
- Nisbet, R. M., Nuttall, S. D., Robert, R., Caine, J. M., Dolezal, O., Hattarki, M., et al. (2013). Structural Studies of the Tethered N-Terminus of the Alzheimer's Disease Amyloid- β Peptide. *Proteins* 81 (10), 1748–1758. doi:10.1002/prot.24312
- Nyunt, T., Britton, M., Wanichthanarak, K., Budamagunta, M., Voss, J. C., Wilson, D. W., et al. (2019). Mitochondrial Oxidative Stress-Induced Transcript Variants of ATF3 Mediate Lipotoxic Brain Microvascular Injury. *Free Radic. Biol. Med.* 143, 25–46. doi:10.1016/j.freeradbiomed.2019.07.024
- Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., et al. (2006). Intraneuronal Beta-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation. *J. Neurosci.* 26 (40), 10129–10140. doi:10.1523/JNEUROSCI.1202-06.2006
- Oddo, S., Caccamo, A., Smith, I. F., Green, K. N., and LaFerla, F. M. (2006). A Dynamic Relationship between Intracellular and Extracellular Pools of A β . *Am. J. Pathology* 168 (1), 184–194. doi:10.2353/ajpath.2006.050593
- Park, J., Wetzel, I., Marriott, I., Dréau, D., D'Avanzo, C., Kim, D. Y., et al. (2018). A 3D Human Triculture System Modeling Neurodegeneration and Neuroinflammation in Alzheimer's Disease. *Nat. Neurosci.* 21 (7), 941–951. doi:10.1038/s41593-018-0175-4
- Pensalfini, A., Albay, R., 3rd, Rasool, S., Wu, J. W., Hatami, A., Arai, H., et al. (2014). Intracellular Amyloid and the Neuronal Origin of Alzheimer Neuritic Plaques. *Neurobiol. Dis.* 71, 53–61. doi:10.1016/j.nbd.2014.07.011
- Petrova, J., Kálai, T., Maezawa, I., Altman, R., Harishchandra, G., Hong, H.-S., et al. (2012). The Influence of Spin-Labeled Fluorene Compounds on the Assembly and Toxicity of the A β Peptide. *PLoS One* 7 (4), e35443. doi:10.1371/journal.pone.0035443
- Ramsay, R. R., Popovic-Nikolic, M. R., Nikolic, K., Uliassi, E., and Bolognesi, M. L. (2018). A Perspective on Multi-Target Drug Discovery and Design for Complex Diseases. *Clin. Transl. Med.* 7 (1), 3. doi:10.1186/s40169-017-0181-2
- Rege, S. D., Geetha, T., Griffin, G. D., Broderick, T. L., and Babu, J. R. (2014). Neuroprotective Effects of Resveratrol in Alzheimer Disease Pathology. *Front. Aging Neurosci.* 6, 218. doi:10.3389/fnagi.2014.00218
- Roy, A., Chandra, K., Dolui, S., and Maiti, N. C. (2017). Envisaging the Structural Elevation in the Early Event of Oligomerization of Disordered Amyloid β Peptide. *ACS Omega* 2 (8), 4316–4327. doi:10.1021/acsomega.7b00522
- Roychaudhuri, R., Lomakin, A., Bernstein, S., Zheng, X., Condrón, M. M., Benedek, G. B., et al. (2014). Gly25-Ser26 Amyloid β -Protein Structural Isomorphs Produce Distinct A β 42 Conformational Dynamics and Assembly Characteristics. *J. Mol. Biol.* 426 (13), 2422–2441. doi:10.1016/j.jmb.2014.04.004
- Rudenko, L. K., Wallrabe, H., Periasamy, A., Siller, K. H., Svindrych, Z., Seward, M. E., et al. (2019). Intraneuronal Tau Misfolding Induced by Extracellular Amyloid- β Oligomers. *J. Alzheimers Dis.* 71 (4), 1125–1138. doi:10.3233/JAD-190226
- Sandberg, A., Luheshi, L. M., Söllvander, S., Pereira de Barros, T., Macao, B., Knowles, T. P. J., et al. (2010). Stabilization of Neurotoxic Alzheimer Amyloid- β Oligomers by Protein Engineering. *Proc. Natl. Acad. Sci. U.S.A.* 107 (35), 15595–15600. doi:10.1073/pnas.1001740107
- Sarubbo, F., Moranta, D., Asensio, V. J., Miralles, A., and Esteban, S. (2017). Effects of Resveratrol and Other Polyphenols on the Most Common Brain Age-Related Diseases. *Curr. Med. Chem.* 24 (38), 4245–4266. doi:10.2174/0929867324666170724102743
- Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012). NIH Image to ImageJ: 25 Years of Image Analysis. *Nat. Methods* 9 (7), 671–675. doi:10.1038/nmeth.2089

- Scopes, D., O'Hare, E., Jeggo, R., Whyment, A., Spanswick, D., Kim, E.-M., et al. (2012). A β Oligomer Toxicity Inhibitor Protects Memory in Models of Synaptic Toxicity. *Br. J. Pharmacol.* 167 (2), 383–392. doi:10.1111/j.1476-5381.2012.01973.x
- Selkoe, D. J., and Hardy, J. (2016). The Amyloid Hypothesis of Alzheimer's Disease at 25 Years. *EMBO Mol. Med.* 8 (6), 595–608. doi:10.15252/emmm.201606210
- Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., et al. (2008). Amyloid- β Protein Dimers Isolated Directly from Alzheimer's Brains Impair Synaptic Plasticity and Memory. *Nat. Med.* 14 (8), 837–842. doi:10.1038/nm1782
- Shea, D., Hsu, C.-C., Bi, T. M., Paranjapye, N., Childers, M. C., Cochran, J., et al. (2019). α -Sheet Secondary Structure in Amyloid β -peptide Drives Aggregation and Toxicity in Alzheimer's Disease. *Proc. Natl. Acad. Sci. U.S.A.* 116 (18), 8895–8900. doi:10.1073/pnas.1820585116
- Silverman, J. M., Gibbs, E., Peng, X., Martens, K. M., Balducci, C., Wang, J., et al. (2018). A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-Beta Oligomers. *ACS Chem. Neurosci.* 9 (7), 1591–1606. doi:10.1021/acchemneuro.7b00469
- Singh, P. K., Kotia, V., Ghosh, D., Mohite, G. M., Kumar, A., and Maji, S. K. (2013). Curcumin Modulates α -Synuclein Aggregation and Toxicity. *ACS Chem. Neurosci.* 4 (3), 393–407. doi:10.1021/cn3001203
- Sperling, R. A., Donohue, M. C., Raman, R., Sun, C.-K., Yaari, R., Holdridge, K., et al. (2020). Association of Factors with Elevated Amyloid Burden in Clinically Normal Older Individuals. *JAMA Neurol.* 77, 735. doi:10.1001/jamaneurol.2020.0387
- Sultana, R., and Butterfield, D. A. (2010). Role of Oxidative Stress in the Progression of Alzheimer's Disease. *J. Alzheimers Dis.* 19 (1), 341–353. doi:10.3233/JAD-2010-1222
- Swerdlow, R. H., Burns, J. M., and Khan, S. M. (2014). The Alzheimer's Disease Mitochondrial Cascade Hypothesis: Progress and Perspectives. *Biochimica Biophysica Acta (BBA) - Mol. Basis Dis.* 1842 (8), 1219–1231. doi:10.1016/j.bbdis.2013.09.010
- Takahashi, R. H., Nagao, T., and Gouras, G. K. (2017). Plaque Formation and the Intraneuronal Accumulation of β -amyloid in Alzheimer's Disease. *Pathol. Int.* 67 (4), 185–193. doi:10.1111/pin.12520
- Teplov, D. B. (2006). Preparation of Amyloid β -Protein for Structural and Functional Studies. *Methods Enzymol.* 413, 20–33. doi:10.1016/S0076-6879(06)13002-5
- Theillet, F.-X., Kalmar, L., Tompa, P., Han, K.-H., Selenko, P., Dunker, A. K., et al. (2013). The Alphabet of Intrinsic Disorder. *Intrinsically Disord. Proteins* 1 (1), e24360. doi:10.4161/idp.24360
- Usman, M. B., Bhardwaj, S., Roychoudhury, S., Kumar, D., Alexiou, A., Kumar, P., et al. (2021). Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives. *J. Prev. Alz Dis.* 8 (4), 1–18. doi:10.14283/jpad.2021.52
- Vandersteen, A., Hubin, E., Sarroukh, R., De Baets, G., Schymkowitz, J., Rousseau, F., et al. (2012). A Comparative Analysis of the Aggregation Behavior of Amyloid- β Peptide Variants. *FEBS Lett.* 586 (23), 4088–4093. doi:10.1016/j.febslet.2012.10.022
- Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., et al. (1999). Amyloid β -Protein Fibrillogenesis. *J. Biol. Chem.* 274 (36), 25945–25952. doi:10.1074/jbc.274.36.25945
- Wang, H., Jiang, T., Li, W., Gao, N., and Zhang, T. (2018). Resveratrol Attenuates Oxidative Damage through Activating Mitophagy in an *In Vitro* Model of Alzheimer's Disease. *Toxicol. Lett.* 282, 100–108. doi:10.1016/j.toxlet.2017.10.021
- Yoshiike, Y., Minai, R., Matsuo, Y., Chen, Y.-R., Kimura, T., and Takashima, A. (2008). Amyloid Oligomer Conformation in a Group of Natively Folded Proteins. *PLoS One* 3 (9), e3235. doi:10.1371/journal.pone.0003235

Conflict of Interest: Author JV was employed by Paramag Biosciences Inc., which retains a license to commercialize the PAL compounds.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor MC declared a shared affiliation with the authors at the time of review.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Hilt, Liu, Maezawa, Rojalin, Aung, Budamagunta, Slez, Gong, Carney and Voss. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.